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ABSTRACT
To sustain the health and viability of renal transplants, adherence to immunosuppressant
therapy (IST) medications is critical. Studies continue to identify decreased adherence rates as
time from transplant increases (Chisholm-Burns, Kwong, Mulloy & Spivey, 2008; Chisholm,
Lance, Mulloy, 2005; Chisholm, Mulloy, & DiPiro, 2005; Nivens & Thomas, 2009). While
previous research has explored the effect of variables known to influence IST adherence in adult
renal transplant recipients, limited studies have explored these variables in a population of renal
transplant recipients with longer time posttransplant intervals. The purpose of this study was to
examine demographic variables, time posttransplant, immunosuppressive agents, health beliefs,
social support, and symptom experience and test their relationship to adherence in a population
of long-term renal transplant recipients.
A cross-sectional correlational design was used to collect data from a convenience
sample of 98 adult renal transplant recipients who were three or more years from transplant.
Participants completed five instruments: 1) demographic survey, 2) the Beliefs About Medicines
Questionnaire (BMQ), 3) the Medical Outcomes Study (MOS) Modified Social Support Survey
(MSSS), 4) the Basel Assessment of Adherence with Immunosuppressive Medication Scales
(BAASIS), and 5) the Modified Transplant Symptom Occurrence and Symptom Distress Scale59R (MTSOSD-59R). A composite adherence score (CAS) consisting of a self-report measure
of adherence (BAASIS), nontherapeutic serum drug assay, and collateral report of adherence as
provided by two transplant clinic professionals was used to determine final adherence group
classification (adherent/nonadherent). Analysis of the relationship between all independent
variables and adherence was conducted using Spearman’s rho correlation coefficient. Mean
scores for medication complexity, health beliefs, social support, and symptom experience were
3

compared between age, gender, and time posttransplant groups using independent-samples t
tests. A logistic regression prediction of probability was conducted to determine which of the
variables that demonstrated a significant relationship to adherence were most predictive of
adherence.
Of the total sample population (N = 98), 39.8% (n = 39) were classified as adherent and
60.2% (n = 59) were nonadherent. Results demonstrated no significant relationship between age
(continuous variable), time posttransplant, immunosuppressant medications (measured by a
medication complexity index), health beliefs, symptom experience, and adherence. Weak, but
significant relationships between age groups (r = -.213, p=.035), tangible social support (r =
.215, p =.017), emotional informational social support (r = .274, p = .003), positive social
interaction support (r = .199, p = .025), total overall social support (r = .274, p =.003) and
composite adherence group classification were found. Older participants (> 55 yrs) were
significantly less adherent than younger (< 54 yrs) participants. Mean scores for emotional /
informational (EMI), positive social interaction (POS), and total social support (MSSS) were
significantly lower in nonadherent participants. Regression results indicated the overall model of
two predictors (age grouped [< 54 yrs; > 55 yrs] and EMI social support subscale) was
statistically reliable in distinguishing between adherent and nonadherent participants (-2 Log
Likelihood 116.244; Goodness-of-Fit x2 (2) = 13.664, p = .001), correctly classifying 69.1% of
the cases.
Findings from this study contribute to the body of research exploring predictors of
immunosuppressant adherence in long-term renal transplant recipients. Data suggest both
younger age (< 55) and categories of social support predict adherence in long-term renal
transplant recipients. Healthcare providers caring for renal transplant recipients long-term
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should consider annually assessing older participants for adherence as well as for changes in
social networks.
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CHAPTER ONE: INTRODUCTION

The Problem
To sustain the health and viability of renal transplants, adherence to a lifelong regimen of
immunosuppressant therapy (IST) is critical. Within the adult renal transplant population,
nonadherence to IST medications has been identified as contributing substantially to increased
risk of both acute and late acute rejection as well as increased graft loss with odds of graft failure
increasing in recipients identified as nonadherent (Butler, Roderick, Mullee, Mason, & Peveler,
2004; Nevins & Thomas, 2009). In addition, studies continue to identify decreased adherence
rates as time posttransplant increases (Chisholm-Burns, Kwong, Mulloy & Spivey, 2008;
Chisholm, Lance, Mulloy, 2005; Chisholm, Mulloy, & DiPiro, 2005; Nivens & Thomas, 2009).
While advances in medicine and the development of more effective IST regimens have resulted
in one year survival rates that exceed 90%, efforts continue to focus on reducing the incidence of
acute rejection and improving long-term outcomes (United States Renal Data Systems [USRDS],
2010). Given the association of increased time posttransplant with IST nonadherence,
exploration of factors that contribute to long-term IST adherence is warranted if long-term renal
transplant outcomes are to improve.
Background
Within the adult renal transplant population, IST nonadherence rates vary widely (8%65%) with an average self-reported nonadherence rate of 28% (Denhaerynck, et al. 2005). A
more recent meta-analysis exploring rates of nonadherence across adult solid organ transplant
1

recipients concluded immunosuppressant nonadherence to be highest in renal transplant
recipients (36%); the rate was more than twice the rate observed in heart recipients, and over five
times greater than liver recipients (Dew et al. 2007). In addition, individual medical costs
associated with persistent low adherence increased individual 3 year medical costs by over
$12,000 (Pinsky et al. 2009).
Nonadherence with IST therapy is identified as contributing substantially to a median
36% (14%-65%) of graft loss (Butler, Roderick, Mullee, Mason, & Peveler, 2004). In a
retrospective cohort study of 15,525 renal transplant recipients, the incidence of graft failure was
11.5% in recipients identified as poorly adherent (Pinsky, et al. 2009). Even minor deviations in
IST dosing schedules have been associated with the development of adverse outcomes and graft
rejection (Nevins & Thomas, 2009; Nevins, Kruse, Skeans, & Thomas, 2001; Schäfer-Keller,
Lyon, Van-Gelder, & De Geest, 2006). In a retrospective analysis of IST dose reduction and
discontinuation, dose reductions greater than 50% were associated with an increased hazard of
graft loss while dose discontinuation resulted in an 8-fold increase in graft loss (Takemoto,
Pinsky, Schnitzler, Lentine, Willoughby, Burroughs, & Bunnapradist, 2007).
The World Health Organization (WHO, 2003) in defining adherence, captured the
multidimensional nature of the concept. Categories of influencing variables included in the
definition were socioeconomic, patient-related, condition-related, therapy-related, and healthcare
system/healthcare team-related variables. All categories of variables have been explored within
the adult renal transplant population.
Of the therapy-related variables known to influence IST adherence, increased time from
transplant has been a factor in IST nonadherence across the majority of studies (Chisholm-Burns,

2

Kwong, Mulloy, & Spivey, 2008; Chisholm, Mulloy, & DiPiro, 2005; Chisholm, Vollenweider,
Mulloy, Jagadeesan, Wynn, Rogers, et al., 2000; Ichimaru, Kakuta, Okumi, Imamura, Isaka,
Nonomra, Kojima, Okuyama, & Takahara, 2008; Nevins & Thomas, 2009; Vasquez, Tanzi,
Benedetti, & Pollak, 2003). While substantial nonadherence with a single IST medication
(18%) has been identified as early as one month following discharge (Nevins, Kruse, Skeans, &
Thomas, 2001), persistent reductions in mean adherence rates for the same IST medication has
been found to continue up to four years following initial transplant, supporting results obtained
in earlier studies (Nevins & Thomas, 2009). In addition, one isolated study classified time
posttransplant in quartiles. Authors concluded quartile 1 (< 4 years posttransplant) as being
significantly associated with higher adherence and noted for every year of increase in time
posttranplant, adherence decreased by 0.3% (Chisholm-Burns, et al. 2008). Increased time
posttransplant remains a nonmodifiable therapy-related factor associated with increased risk of
nonadherence to IST medications.
Other variables identified as influencing adherence-immunosuppressant therapy, beliefs
about medicines, social support, and symptom experience- have been explored in a few recent
studies. In addition, studies exploring these variables include sample populations with recipients
as early as six months to two years posttransplant. To date, no study has explored these
variables in a group of renal transplant recipients identified as “long-term” yielding support
for exploration in a more long-term population.
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Statement of Problem
Despite the performance of over 16,000 kidney transplants in 2010, over 96,000 patients
currently await renal transplantation in the United States (United Network for Organ Sharing
[UNOS], 2009). Given the current shortage of available organs, efforts continue to focus on
improving long-term outcomes. While previous research has explored the effect of all categories
of influencing variables on IST adherence in adult renal transplant recipients, limited studies
have explored these variables in a population of renal transplant recipients with longer time
posttransplant intervals.
Study Purpose/Aim
The purpose of this study was to examine demographic variables, time posttransplant,
immunosuppressive agents, health beliefs, social support, and symptom experience and test their
relationship to adherence based upon the Health Decision Model (Eraker, Becker, Strecher, &
Kirscht, 1984).
Definition of Terms
Table 1 summarizes key terms as defined and operationalized in this study.
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Table 1 Definition of Terms
Term
Age

Theoretical Definition
Age of the participant in years at the time of
study enrollment.
Younger = < 54 years; older = > 55 years of
age.

Operational Definition
Date of birth as measured by a
demographic questionnaire. Age in
years at the time of study enrollment
was calculated using date of study
enrollment and date of birth.

Long-Term

Long-term was defined as three or more years
from transplant.

Long-term was defined by the date
of initial transplant as measured by a
demographic questionnaire.

Time Posttransplant

Time posttransplant was defined as the total
number of years since the patient’s date of
renal transplantation.

Time posttransplant was measured
by a demographic questionnaire.
Time posttransplant in years was
calculated using both the date of
study enrollment and the date of
renal transplantation.

Immunosuppressive Agents

Immunosuppressive agents were defined as
the names of medication the patient is taking
for the purpose of immunosuppression.

Immunosuppressive agents were
identified by a demographic
questionnaire and included the
medication names. Medication
complexity was measured using a
calculated medication complexity
index-the product of the total
number of IST medications, number
of pills taken per day, and the
number of times per day taking
medications.

Health Beliefs

Health beliefs were defined as personal
convictions that influence individual health
behaviors (Moorhead, Johnson, Maas, &
Swanson, 2008).

Health beliefs were measured by the
Beliefs about Medicines
Questionnaire [BMQ) (Horne,
Weinman, & Hankins, 1999).
Possible scores for both BMQ
subscales range from five to 25 with
higher scores indicating stronger
beliefs.
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Term
Social Support

Theoretical Definition
Social support was defined as the existence or
availability of a person or network of people
that rely, care, and love an individual and on
whom that same individual can rely (Sarason,
Levine, Basham, & Sarason, 1983).

Operational Definition
Social support was measured by the
18 item Medical Outcomes Study
(MOS) Modified Social Support
Survey (MSSS) subscales and total
instrument scores (Sherbourne &
Stewart, 1991) The18 items
represent the multiple dimensions of
social support-tangible, affectionate,
emotional / information, positive
social interaction. Possible scores
range from 0-100 with higher scores
indicating greater perceived support.

Symptom Experience

Symptom experience was defined as both
symptom occurrence representing the
cognitive component of the frequency,
severity and duration of symptoms, and
distress representing the emotional burden
that results (Kugler, Geyer, Gottlieg, Simon,
Haverich, & Dracup 2009).

Symptom experience was measured
by the Modified Transplant
Symptom Occurrence and Symptom
Distress Scale (MTSOSD-59R)
(Dobbels, Moons, Abraham, Larsen,
Dupont & De Geest, 2008). Ridit
scores were calculated to rank order
symptom occurrence and symptom
distress. Overall individual
symptom occurrence and symptom
distress ridit scores were compared.

Immunosuppressant
Nonadherence

Immunosuppressant nonadherence was
defined as “deviation from the prescribed
medication regimen sufficient to influence
adversely the regimen’s intended effect”
(Fine, Becker, De Geest, Eisen, Ettenger, et
al., 2009, p. 36).

Immunosuppressant nonadherence
was measured as a composite
adherence score that consisted of
self-reported nonadherence as scored
on the Basel Assessment of
Adherence with Immunosuppressive
Medications Scale (BAASIS),
collateral-reported nonadherence of
two clinicians, and nontherapeutic
assay variability. Participants were
classified as adherent or
nonadherent.
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Research Question and Hypotheses
Based on the Health Decision Model and review of the literature, the primary research
question to be addressed was which of six predictor variables-demographic variables, time
posttransplant, immunosuppressive agents, health beliefs, social support, and symptom
experience-are most influential in predicting IST adherence in long-term adult renal transplant
recipients? The following hypotheses were tested in this study:
Hypothesis 1
There will be a significant negative relationship between the predictor variable of time
posttransplant as measured in years and composite adherence group classification.
Hypothesis 2
There will be a significant relationship between the predictor variable of age as measured
in years and composite adherence group classifications.
Hypothesis 3
There will be a significant relationship between medication (IST) complexity index
scores and composite adherence group classifications.
Hypothesis 4
There will be a significant difference in IST complexity index scores between composite
adherence group classifications.
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Hypothesis 5
There will be a significant relationship between the predictor variable of health beliefs as
measured by BMQ Necessity and BMQ Concerns subscale scores and composite adherence
group classifications.
Hypothesis 6
There will be a significant difference in BMQ Necessity subscale, BMQ Concerns
subscale, and BMQ Necessity/Concerns differential scores between composite adherence group
classifications.
Hypothesis 7
There will be a significant positive relationship between the predictor variable of social
support as measured by total MSSS scores and composite adherence group classifications.
Hypothesis 8
There will be a significant difference in MSSS subscale and total scale scores between
composite adherence group classifications.
Hypothesis 9
There will be a significant negative relationship between the predictor variable of
symptom experience as measured by MTSOSD-59R total ridit scores and composite adherence
group classifications.
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Hypothesis 10
There will be a significant difference in MTSOSD-59R total ridit scores between
composite adherence group classifications.
Study Significance
As time posttransplant increases, follow-up care shifts from the acute care phase provided
by transplant clinics during the first year following transplantation to long-term health promotion
and maintenance provided by primary healthcare providers outside of the transplant clinic
setting. Having an understanding of the modifiable factors that contribute to successful long
term IST adherence can guide practitioners in developing and implementing appropriate
interventions to sustain long- term IST adherence improving long-term graft outcomes.
Nonadherence with immunosuppressive medication in the adult renal transplant
population impacts the health and viability of graft outcomes due to a variety of influencing
factors. As the focus shifts to improving long-term graft outcomes, comprehensive exploration
of risk factors for adherence in long-term populations helps delineate risk profiles. Research
regarding the influence of risk factors for nonadherence in long-term renal transplant populations
has yet to be conducted and this study will add to the current body of knowledge. Chapter 2
provides a review of literature relevant to the problem under study, illustrates the framework that
guided the study, and identifies gaps in the literature to be addressed by the current study.
Chapter 3 addresses methods used to carry out the research, while Chapters 4 and 5 present
findings, discuss conclusions, and outline recommendations for future research.
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CHAPTER TWO: LITERATURE REVIEW
To determine the state of the science of IST adherence research within the adult renal
transplant population, a review of Cumulative Index to Nursing and Allied Health Literature
(CINAHL), PubMed, and PsychInfo databases was conducted using the key search terms of
adherence, immunosuppressant, medication, and renal transplant. Secondary searches were
conducted from the reference lists of selected articles. While all studies selected were published
in the English language, priority was given to studies that were published within the last 10
years. Works older than 10 years considered seminal studies were included in the review.
Studies that explored variables within European populations were included if literature on the
variable under study was limited. Examination of previous research regarding IST adherence
definition and measurement, prevalence and outcomes, and categories of determinants identified
gaps in the current body of knowledge to be addressed by the proposed study.
Defining Adherence
While medication adherence rates of 80% are often cited as acceptable across many
illness categories (Osterberg & Blaschke, 2005), a consensus definition of what constitutes
optimum adherence in adult renal transplant recipients remains elusive. The lack of a clinically
meaningful definition of adherence prevents both the identification of the degree of adherence
necessary to achieve desired pharmacological effects, and the degree of subclinical nonadherence
that increases the risk of adverse outcomes (acute rejection, graft loss). In light of the lack of a
clinically meaningful definition of adherence, researchers have frequently dichotomized
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adherence into an “all or nothing” phenomenon (adherent, nonadherent). Lost in the
dichotomization of the concept of adherence are the dimensions of medication taking (taking,
timing, drug holidays, and dose reductions) that contribute to the multidimensional nature of the
phenomenon.
While multiple studies exploring the prevalence of IST nonadherence in adult renal
transplant recipients have selected 80% adherence as the degree distinguishing adherers from
nonadherers (Chisholm, Lance, & Mulloy, 2005; Chisholm, et al., 2000; Hilbrands, Hoitsma, &
Koene, 1995), the majority of prevalence studies have operationalized IST nonadherence as the
quantity and frequency of missed doses as measured using self-report (De Geest et al., 1995;
Denhaerynck et al., 2006; Frazier, Davis-Ali, & Dahl, 1994; Ghods, Nasrollahzadeh, & Argani,
2003; Hardstaff, Green, & Talbot, 2003; Raiz, Kilty, Henry, & Ferguson, 1999; Teixeira de
Barros & Cabrita, 2000; Vasquez, Tanzi, Benedetti, & Pollak, 2003). A meta-analysis of 36
studies by Butler, Roderick, Mullee, Mason, and Peveler (2004) identified the most common
definition of nonadherence as missing, forgetting, or altering of a dose at least once per month.
Further complicating formulation of a consensus definition is a lack of clarification of what
constitutes a “late” or “missed” dose. While a few studies have defined the timing associated
with a “late” dose as being ingested 2 to 2.5 hours beyond the scheduled time (Schmid-Mohler,
Thut, Wüthrich, Denhaerynck, & De Geest, 2010; Sketris, Waite, Grobler, West, & Gerus, 1994;
Teixeira de Barros & Cabrita, 2000), no studies to date conducted with the adult renal transplant
population have explored clinician and/or patient conceptualizations of a “missed” dose.
The phenomenon of nonadherence has been described using four characteristics: timing,
frequency, origin, and certainty of diagnosis (Chapman, 2004; Hansen, Seifeldin, & Noe, 2007).
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Mirroring the six patterns of medication adherence noted among other chronic illness categories
(Osterberg & Blaschke, 2005) occasional nonadherence has been further delineated into three
subcategories: patients having near perfect adherence, patients adherent to nearly all doses but
with timing irregularities, and patients missing an occasional dose. Intermittent nonadherence
was defined further as patients taking drug holidays 3-4 times yearly. Persistent nonadherers
were further defined as patients taking drug holidays monthly or more often, and complete
nonadherers were identified as patients taking few or no doses of immunosuppressants (Hansen,
et al., 2007). In addition, Hansen et al. (2007) defined the diagnostic certainty of nonadherence
as definite (direct admission of nonadherence by patient), probable, possible or unlikely,
depending upon the evaluation method.
A seminal study conducted by Greenstein and Siegal (2000), identified three profiles of
nonadherent patients. Accidental nonadherers, accounted for the majority of nonadherence in
the study population (47%) and included patients who simply forgot to take IST medications.
Invulnerable nonadherers, accounted for 28% of the study population and included renal
transplant recipients guided by the belief they do not need to take their medications regularly.
Decisive nonadherers, those patients who employed independent decision making habits
ignoring the need for medications, accounted for 25% of the sample population.
Recent studies have attempted to more clearly capture the dimensions of medication
adherence behaviors. A longitudinal study by Russell et al. (2006) of 44 adult renal transplant
recipients identified four patterns of IST adherence: 1) taking medications on time, 2) taking
medications on time with late / missed doses, 3) rarely taking medications on time, and 4) taking
medications morning and/or evening doses late, and those who missed doses. A prospective
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cohort study conducted by Denhaerynck et al. (2007) captured similar patterns of nonadherence
while studying the prevalence of IST nonadherence in 249 adult renal transplant recipients by
exploring the percentage of taking adherence (number of prescribed doses), dosing adherence
(days with correct dosing), timing adherence (taken within 25% of prescribed intervals), and
drug holidays. With the advent of more self-report adherence instruments measuring all
dimensions of medication taking-timing, taking, drug holidays (missed, omitted) and dose
reduction-more studies exploring determinants of adherence are capturing the entire nature of the
concept.
Current scholarly activities conducted within the transplant population have worked
toward the formulation of solutions to address issues of definition and measurement in IST
adherence research. A more succinct definition of nonadherence, intended to better represent the
dynamic nature of a patient’s medication taking behavior, emerged during a consensus
conference on nonadherence to immunosuppressant medications (Fine, Becker, De Geest, Eisen,
Ettenger et al, 2009). Understanding that satisfactory adherence results when gaps between
dosing history and the prescribed regimen have no effect on clinical outcomes, experts have
conceptually defined nonadherence as “deviation from the prescribed medication regimen
sufficient to influence adversely the regimen’s intended effect” (Fine et al, 2009, p. 36.).

Measuring Adherence
IST adherence studies have used both direct and indirect methods of measurement, each
with identifiable limitations. Direct monitoring methods (direct observation of intake, blood /
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urine biological drug assays, biological markers), have the disadvantage of being inconvenient to
the patient, influenced by increased adherence prior to sampling, affected by variations in
individual metabolism, and at times, prone to lab error (Chisholm, 2002; Hansen, et al. 2007).
Assays obtained for medications with a short half-life may only provide information about
patterns of adherence over the prior few days with no information regarding long-term
adherence. In addition, therapeutic monitoring of IST medications such as mycophenolate
mofetil (Cellcept) requires multiple blood samples during dosing intervals leading to increased
costs, patient inconvenience, and limited feasibility across clinical settings (Jeong & Kaplan,
2007). Indirect measurement methods (patient self-report, collateral reports, prescription refill
rates, pill counts, electronic drug monitoring, health outcomes), while often more simple and
feasible, are not without disadvantages. Patients often under report nonadherence, prescription
refill rates fail to provide information related to characteristics of nonadherence; pill counts fail
to consider multiple sources of medication; and electronic monitoring fails to prove ingestion
(Chisholm, 2002; Hansen, et al. 2007).
Electronic monitoring, frequently considered the gold standard measure of adherence, has
limitations that challenge both internal and external measurement validity. A study by
Denhaerynck et al. (2008) examined assumptions needed for internal and external validity of
electronic monitoring measurement. The study tested validity through evaluation of: 1) correct
functioning of electronic monitoring equipment, 2) correspondence of cap openings with actual
dose intake, and 3) the influence of electronic monitoring on a patient’s normal adherence
behavior. Several assumptions of internal and external validity were not satisfied: 1) equipment
or cap malfunctions, 2) self-reported mismatches between cap openings and drug intake in 62%
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of patients, and 3) adherence decreased over 5 weeks indicating an intervention effect of the
measurement method (Denhaerynck et al., 2008).
Despite the increased use of electronic monitoring, the majority of studies continue to
rely heavily on self-report measures of adherence (surveys, questionnaires, interviews) (Brown et
al., 2009; De Geest et al., 1995; Denhaerynck et al. 2007; Frazier et al. 1994; Ghods et al. 2003;
Goldfarb-Rumyantzev, Wright, Ragasa, Ostler, Van Orden, Smith et al., 2011; Greenstein &
Siegal, 1998; Kalil, Heim-Duthoy, & Kasiske, 1992; Nevins & Thomas, 2009; Raiz et al. 1999;
Sharma, Gupta, Tolani, Rathi, & Gupta, 2000; Sketris, Waite, Grobler, West, & Gerus, 1994;
Teixeira de Barros & Cabrita, 2000; Vasquez, Tanzi, Benedetti, & Pollak, 2003). Though prone
to response bias and criticized for providing little insight into adherence characteristics, self-report measures of adherence are recognized as the most feasible method of monitoring
adherence (Butler, Peveler, Roderick, Horne, & Mason, 2004). A study comparing
self-report adherence with electronic measurement concluded that self-report adherence,
conducted in the setting of a confidential interview, to be the better measure for detecting missed
doses and erratic dose timing (Butler, et al. 2004). In addition, a recent meta-analysis of 147
studies conducted within the solid organ transplant populations concluded self-report
assessments of adherence to yield the highest rates of nonadherence (Dew et al. 2007).
To date, no measure of adherence (direct, indirect) has emerged as a gold standard.
Current literature supports the use of a combination of measurement methods to increase
diagnostic accuracy of subclinical nonadherence (Butler, et al. 2004; Schäfer-Keller, Steiger,
Bock, Denhaerynck, & De Geest, 2008). A recent study exploring the diagnostic accuracy of
current IST adherence measurement methods identified a composite score composed of
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information obtained from patient self-report and/or clinician collateral reports, and/or
nontherapeutic assay results as having the highest sensitivity to nonadherence (72.1%) (SchäferKeller, et al. 2008). While specificity of the same composite score was low, evidence supports
continued use of the composite score as a screening measure. Given the identified limitations
associated with current methods of measurement, the continued use of measures of self-report as
one component of assessing subclinical nonadherence is supported.
Prevalence and Outcomes of Nonadherence
Variations in definition and measurement prevent accurate representation of both the
prevalence of IST nonadherence and the effect of IST nonadherence on clinical outcomes. The
majority of studies attempt to demonstrate the effect of IST nonadherence on the clinical
outcomes of acute and/or late rejection and graft failure and/or loss. A few isolated studies
focusing on economic outcomes have explored with impact of IST nonadherence on healthcare
costs.
Advances in immunosuppression have reduced the incidence of acute rejection episodes
in the first year following transplantation (Denhaerynck et al. 2009). Despite the decrease in
acute rejection rates, significant improvements have not occurred in long-term graft survival
(Meier-Kriesche, Schold, Srinivas, & Kaplan, 2004). Early allograft damage, attributed to
episodes of acute rejection, contributes to the development of chronic allograft nephropathy
(chronic rejection) (Pascual, Theruvath, Kawai, Tolkoff-Rubin, & Cosimi, 2002). Acute
(occurring within the first year) and late acute rejection episodes (occurring > 1 year from
transplant), both major risk factors for chronic rejection (chronic allograft nephropathy), have
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been found to be strongly associated with late graft loss (De Geest et al. 1995; Joseph et al. 2001;
Sijpkens, Doxiadis, Mallat, Fijter, & Bruijn, 2003; Nevins & Thomas, 2009). In renal transplant
recipients with ten years of graft function, allograft nephropathy (chronic rejection) was one of
the identified causes of most graft loss (Matas, Gillingham, Humar, Kandaswaym, Sutherland,
Payne, Dunn, & Najarian, 2008).
While the majority of prospective studies exploring IST nonadherence identified higher
rates of acute rejection, graft loss, graft failure, and greater association with late acute rejection
episodes in recipients identified as nonadherent (Morrissey et al., 2005; Nevins & Thomas, 2009;
Brown et al. 2009; Nevins, Kruse, Skeans, & Thomas, 2001; Pinkey et al. 2009; Vlaminck et al.
2004; Hilbrands, Hoitsma, & Koene, 1995), two recent studies yielded conflicting results. A
retrospective cohort study conducted by Denhaerynck and colleagues (2009) reported no
association between nonadherence and graft failure / graft function in a sample of renal
transplant recipients at least one year from transplant followed over a five year period. One
study limitation identified by the researchers as contributing to these conflicting results was the
exceptionally high rate of adherence (98.4%) that might have exceeded the threshold necessary
to detect the effect of nonadherence. Other noteworthy research processes involved in the study
included an adherence enhancing intervention carried out in nonadherent patients immediately
following baseline measurement. In addition, the authors concluded that the use of newer, less
nephrotoxic IST medications taken by 62% of the sample (mycophenolate mofetil, tacrolimus,
sirolimus) may have reduced the detrimental effects of nonadherence on long-term renal function
resulting in the inability to determine the mediating effects of nonadherence in the relationship
(Denhaerynck et al. 2009). A more recent prospective cohort study of 243 deceased donor
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recipients from 8 transplant centers conducted by Israni and colleagues (2011) followed
participants 18 years of age and older who were recruited at the time of transplant and followed-up with telephone interviews after discharge and every six months for 36 months. Medication
adherence was measured using electronic cap monitoring systems (eDEM© cap) during the
initial 6 months posttransplant. While acute rejection occurred in 10% (n =25) of the sample,
adherence was not associated with acute rejection or decline in glomerular filtration rate (Israni
et al., 2011). Possibly contributing to the lack of association between adherence and outcomes in
this study were two factors: 1) the limited time monitoring adherence potentially not
representing adherence patterns during the remaining study period, and 2) electronic monitoring
may have introduced measurement error by underestimating the amount of nonadherence
(inability to prove ingestion) (Israni et al. 2011).
Studies exploring the economic outcomes associated with IST nonadherence are limited.
Given that 36.4% of graft failures that occur within the first year following transplant result from
IST nonadherence, $100 million in additional healthcare costs can be attributed to first year graft
failures (Hansen, Seifeldin, & Noe, 2007). In addition, assuming 53% of rejection episodes were
likely attributed to IST nonadherence, $13-$16 million dollars was necessary to treat and prevent
graft loss (Hansen, Seifeldin, & Noe, 2007). More recent studies by Pinsky and colleagues
(2009) and Evans and colleagues (2010) identified cost-related outcomes associated with
nonadherence. Pinksy et al. (2009) in a survey of 254 U.S. renal transplant programs reported
68% of programs reported deaths and graft loss associated with cost-related IST medication
nonadherence while Evans et al. (2010) in a retrospective study of 15, 525 first time renal
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transplant recipients with Medicare coverage through the first year identified a $12,840.00
increase in individual three year healthcare costs in recipients with persistently low adherence.
Determinants of Nonadherence
Five categories of interrelated risk factors, reflective of the World Health Organization’s
(2003) categories, have been identified as influential to IST nonadherence in adult renal
transplant recipients: 1) socioeconomic, 2) patient-related, 3) condition -related, 4) therapy related, and 5) healthcare system / healthcare provider- related factors.
Socioeconomic-Related Variables
Socioeconomic factors, while relatively nonmodifiable in nature, have been the most
widely studied factors within the adult renal transplant population. Consistent with global
studies exploring predictive values of these factors (age, gender, race, income level, education)
across illness categories (World Health Organization [WHO], 2003), results have been
inconsistent within the adult renal transplant population. Similar to the multiple conceptual and
operational definitions of adherence, multiple representations of socioeconomic variables within
the adult renal transplant population (age, education, race, income level) may possibly contribute
to the inconsistent findings.
The majority of studies conducted within the adult population consistently conclude
younger age as being associated with nonadherence (Chisholm et al. 2005; Chisholm,
Williamson, Goldfarb-Rumyantzev, Wright, Ragasa, Ostler, Van Orden, et al. 2011; Lance, &
Mulloy, 2007; Denhaerynck et al. 2007; Frazier et al. 1994; Ghods et al. 2003; Greenstein &
Siegal, 2000; Schweizer et al. 1990; Sketris et al. 1994). A review conducted by Denhaerynck et
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al. (2005) suggested that studies failing to associate a younger age with nonadherence lacked a
significant subsample of adolescents. The authors hypothesized that without a representative
sample of adolescents, adherence might remain stable over the lifespan as long as cognition
remained intact (Denhaerynck et al. 2005). Contrary to these studies, two recent studies reported
findings that indicate nonadherence increases with age. In a study by Chisholm et al. (2008)
results of the study found nonadherence increased as age increased. The second study identified
86% of the study population consisting of adults age 55 and older (mean sample age of 60.38
years) as being nonadherent with medications (Russell, Centingok, Hamburger, Owens,
Thompson et al., 2010).
A few isolated studies have attempted to delineate age ranges of both younger and older
recipients. Schwizer, Rovelli, Palmeri, Vossler, Hull, and Bartus (1990) differentiated between
younger (< 20 years) and older (> 40 years) in age as reported in years, while Greenstein and
Seigel (1998) reported older (mean age 47.9 years) and younger (mean age 41.1 years) recipients
in terms of mean ages. Nevins, Kruse, Skeans, and Thomas (2001) defined “young” as < 21
years of age. A 1999 study comparing symptom frequency and distress in patients delineated 40
years of age as the median age separating older from younger patients (Teixeira De Barros &
Cabrita, 1999). Chisholm-Burns and colleagues (2008) concluded that older recipients (those 60
years of age and older) were more likely to be nonadherent than younger recipients (those
between age 18-60 years of age).
Variations exist in the operationalization of education with studies delineating low versus
high levels of education; elementary, high school, and college; while others delineate education
in the total number of years completed. Studies exploring the association of educational level
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with adherence yielded similar conflicting results with no consistent association with IST
nonadherence identified (Goldfarb-Rumyantzev et al. 2011; Butler et al. 2004; De Geest et al.
1995; Frazier et al. 1994; Ghods et al. 2003; Greenstein & Siegal, 1998; Raiz et al. 1999;
Vasquez et al. 2003).
Studies exploring both race and income level have yielded mixed results making
determination of a consistent relationship with IST adherence difficult (see Table 3). Multiple
operational definitions of race evident in the current body of knowledge include: 1) whites,
nonwhites; 2) black, 3) Caucasian, African American, Hispanic, and 4) black, nonblack.
Socioeconomic status operationalized in terms of income level (mean annual income level),
socioeconomic class (low, middle, high), and employment status (part-time, full-time,
unemployed, student, retired; white collar, blue collar occupation) equally contribute to mixed
results.
Patient-Related Variables
Of greater interest to clinicians are the modifiable patient-related or condition-related
factors influencing the origins of IST adherence behavior. Health beliefs, conceptualized as the
personal convictions that influence health behaviors (Moorhead, Johnson, Maas, & Swanson,
2008), encompass a combination of attitudes that include the perceived susceptibility of
experiencing a harmful condition, the perceived seriousness of a condition, the perceived benefit
the performance of the health behavior has in reducing the threat of the condition, and perceived
barriers related to the negative aspects of a health behavior (Champion, 1984). A perceived need
for medication (health beliefs) was found to contribute to IST nonadherence in several studies
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(Butler et al., 2004; De Geest et al., 1995; Greenstein, & Siegal, 2000; Greenstein & Siegal,
1998; Raiz et al. 1999).
Qualitative studies support findings obtained through quantitative methods with regards
to health beliefs. A phenomenological study by Orr et al. (2007) of 26 adult renal transplant
recipients identified the theme of health beliefs as one of four patient perceived factors that
influence IST medication adherence.
Research examining the effect of social interactions (social networks, social support) on
IST adherence is limited. Social network variables such as living alone and/or being unmarried
have been found to be associated with nonadherence (Butler et al. 2004; De Geest et al. 1995;
Frazier et al. 1994; Raiz et al. 1999; Teixeira de Barros & Cabrita, 2000). Social support,
defined as the existence or availability of a person or network of people that rely, care, and love
an individual and on whom that same individual can rely (Sarason, Levine, Basham, & Sarason,
1983) is categorized as both perceived social support (individual’s perception of available
support) and received social support (support actually received by an individual) (Dobbels,
Verleden, Vanhaecke, & DeGeest, 2006). Additional dimensions of social support identified in
the literature include: 1) source of support, 2) satisfaction of support, and 3) type of support
(emotional, instrumental or practical, informational, affirmational) (Chisholm-Burns, Spivey, &
Wilks, 2010). The effect of social support on IST adherence among organ transplant recipients
varies across studies. A meta-analysis by Dew et al. (2007) found poorer social support in solid
organ transplants (kidney, heart, liver, pancreas, kidney/pancreas and heart and lung) to be
associated with significantly greater IST nonadherence though the effect size was weak. While
early multivariate models within the adult renal transplant population identified higher levels of
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social functioning as associated with adherence, additional study results are inconsistent
(Greenstein & Siegal, 2000). Kiley et al. (1993) identified nonadherence in renal transplant
recipients to be associated with perceived amount of social support, while at the same time
Frazier et al. (1994) found no relationship between social support and adherence. By contrast, a
recent study conducted by Chisholm-Burns et al. (2010) identified a significant positive
relationship between two types of social support (affectionate and instrumental
support) and IST adherence.
Additional research into the contribution of the categories and dimensions of social
support on long-term IST adherence is warranted due to the changing nature of both the scope of
healthcare services and social support networks as time from transplant increases.
Condition-Related Variables
Symptom experience can be conceptualized as both symptom occurrence and symptom
distress (Kugler, Geyer, Gottlieb, Simon, Haverich, & Dracup, 2009).

Representing the

cognitive component of symptom experience, symptom occurrence can be quantified by the
frequency, severity, and duration of a given symptom, while symptom distress captures the
emotional burden association with the symptom (Kugler et al. 2009). Though most often
investigated within the context of its effect on quality of life, symptom experience (symptom
occurrence / symptom distress), noted to be associated with an increased risk for nonadherence
in early studies (Butler et al. 2004; Denhaerynck et al. 2007; De Geest et al. 1995; Greenstein &
Seigel, 1998; Sketris et al. 1994; Teixeira de Barros & Cabrita, 1999). Symptom experience has
only been explored recently in one isolated study conducted within the European population and
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not within the context of adherence research but rather as a method of evaluating symptom
profiles associated with immunosuppressant therapy (Koller, Denhaerynck, Moons, Steiger,
Bock, & De Geest, 2010). In light of evolving immunosuppressant regimens, quantitative
exploration of the effect of symptom experience on adherence is warranted.
Therapy-Related Variables
A variety of independent variables categorized as therapy-related variables have been
explored in previous IST adherence studies. With the typical cost of IST therapy alone
exceeding $10,000 annually, a few isolated studies have explored the effect of cost on IST
adherence. Despite receiving medications free of charge, two studies concluded IST adherence
to decrease over time suggesting drug cost alone as not influencing adherence (Chisholm et al.
2005; Chisholm et al. 2000).
Across the majority of studies, increased time from transplant, conceptualized as months,
years, and mean years/months since initial transplant, has demonstrated association with
nonadherence (Chisholm-Burns et al. 2008; Chisholm et al. 2005; Chisholm et al. 2000;
Greenstein & Seigel, 2000; Greenstein & Seigel, 1998; Hardstaff, Green, & Talbot, 2003;
Nevins, Kruse, Skeans, & Thomas, 2001; Nevins & Thomas, 2009; Sketris et al. 1994; Vasquez
et al. 2003). Additional findings by Chisholm-Burns et al. (2008) identified a trend toward
higher adherence rates in recipients four years or less posttransplant indicating a possible need
for the implementation of interventions to support adherence as patients approach four to five
years from transplant.
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Across chronic illness categories, complex dose regimens have been found to contribute
to poor medication adherence. In a systematic review of 76 studies encompassing a variety of
disorders using electronic monitoring as the measure of adherence, researchers concluded mean
dose-taking adherence declined as the number of daily doses increased (Claxton, Cramer, &
Pierce, 2001). Adherence was significantly higher in once-daily dosing regimens versus three
and four times daily regimens (Claxton et al., 2001).
Studies conducted within the transplant population have yielded similar results. In a
study of 182 renal transplant recipients taking cyclosporine as a component of either dual or
triple IST therapy, Sketric and colleagues (1994) noted the number of overall prescription
medications significantly affected adherence. A later study, exploring adherence in a sample of
278 adult recipients recruited at the time of transplant and followed during the first year,
identified a significant association between once daily versus twice daily dosing frequencies
(Weng et al., 2005). Studies exploring the impact of medications prescribed to manage
comorbid conditions in addition to IST medications noted similar results (Vasquez, et al. 2003;
Goldfarb et al. 2009).
Efforts to improve IST medication adherence have led to the development of a reliable,
prolonged formulation of tacrolimus (Advograft). Available since 2007, the more convenient
once daily dosing regimen was preferred by 99.4% of a sample (n=1832) of European adult renal
transplant recipients undergoing conversion from twice-daily to once-daily dosing with
tacrolimus (Guirado, Cantarell, Franco, Huertas, Fructuoso, et al. 2011). Thirty-four percent of
the same study population reported improved adherence, as measured by verbal self-report of
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any deviations from dose schedule. Increased adherence was postulated to be due to increased
convenience of not have an evening medication dose (Guirado et al. 2011).
Healthcare System-Related Variables
The influence of the healthcare system has been explored in two studies. Denhaerynck
and colleagues (2006) compared IST adherence rates of American and European renal transplant
recipients failing to identify specific healthcare system factors at the micro or macro level as
significantly influencing nonadherence. An additional study conducted by Weng et al. (2005)
identified transplant center characteristics as independently associated with adherence noting that
the center may serve as a proxy for characteristics that promote adherence (cultural competency,
staffing levels, frequency and quality of contact with providers, effectiveness of education). A
recent study explored the effect of primary insurance on the risk of nonadherence (Chisholm et
al. 2007). Researchers concluded that recipients with Medicare coverage were significantly less
likely to be nonadherent to IST medications compared to those recipients who did not have
Medicare coverage (Chisholm et al. 2007). A variety of private and government (Medicare,
Medicaid) payor options are available to individuals undergoing renal transplantation with
varying conditions of coverage. Medicare is the primary payor for approximately 70% of renal
transplant recipients and a secondary payor for others (Woodward, Schnitzler, Lowell,
Spitznagel, & Brennan, 2001). For patients eligible for Medicare coverage at the time of their
transplant due to age, disability or entitlement secondary to end stage renal disease, Medicare
pays 80% of costs associated with IST therapy (Cleemput, Kesteloot, Vanrenterghem, & De
Geest, 2004). Duration of IST coverage varies under Medicare with individuals eligible solely
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due to end stage renal disease entitlement losing coverage after 36 months. Though a study
conducted by Yen and colleagues (2004) concluded extending Medicare Coverage of IST
therapy for the life of a kidney transplant would result in both improved graft survival rates and
significant cost savings to society, only a single isolated study has explored the association of
payor type with nonadherence. With over 15,000 transplant recipients securing Medicare
benefits by entitlement (U.S. Renal Data Systems, 2009), coupled with the increased interest in
preemptive transplantation as a strategy to improve outcomes, the potential for an increase in the
number of individuals with limited IST coverage warrants further exploration as a risk factor for
nonadherence.
While research has identified several variables influential to IST adherence, to date, no
study to date has focused on predictor variables that significantly influence IST adherence in a
population of long-term (3 years or more from transplant) renal transplant recipients. Given the
effect of nonadherence on graft outcomes and the influence of increased time since transplant on
IST adherence, further exploration and identification of influencing factors in long-term adult
renal transplant recipients is warranted if long-term outcomes are to improve.
Framework
Guiding the conduct of this study is the Health Decision Model, a third generation
representation of the Health Belief Model proposed by Eraker, Kirscht, and Becker (1984).
Within the context of adherence, the Health Belief Model (Becker, 1974) attributes the
probability of adherence behavior to the interaction among an individual’s perception of illness
susceptibility and severity of a given health outcome with the benefits and barriers likely to be

27

encountered with a prescribed intervention. The Health Decision Model focuses on health
decisions and the influence of patient preferences, health beliefs, and modifying factors on an
individual’s adoption of a health behavior (see Figure 1).
The ability of an individual to express preferences that influence health decisions has
been associated with both decision analysis and behavioral decision theory (Eraker & Politser,
1982). Decision analysis provides a systematic process whereby individuals express preferences
about risks and benefits associated with a therapeutic action. Behavioral decision theory extends
decision analysis by identifying rules used by individuals to reduce complex decisions into
simple ones (Eraker & Politser, 1982). Ultimately, the preferred course of action adopted by the
individual reflects the outcome that offers the highest value.
Health beliefs and several categories of modifying factors identified as components of the
Health Decision Model are congruent with variables identified as contributing to adherence
within the adult renal transplant population. Variables to be explored in this study, reflective of
categories represented in the Health Decision Model include: 1) specific health beliefs regarding
the necessity of prescribed medications as quantified by the Beliefs About Medicines
Questionnaire, 2) symptom experience associated with the prescribed IST regimen as quantified
by the Modified Transplant Symptom Distress/Symptom Occurrence scale, 3) social support as
quantified by the Modified Social Support Survey, and 4) demographic variables categorized
consistent with the Organ Transplant and Procurement Network national database (2012) as
available. As illustrated by the bidirectional arrows and feedback loops depicted in the Health
Decision Model, adherence behavior can also change health beliefs. In addition, while the
degree of influence of many modifying factors may vary from individual to individual, this study
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will seek to identify which combination of variables best predicts the probability of adherence
behavior in the sample population.
Lacking in the current representation of health decisions and health behavior adherence
(see Figure 1) are both the dimensions of medication taking adherence (taking, timing, omitting/
drug holiday, dose reduction) and the profiles of nonadherent individuals (accidental,
invulnerable, decisive) identified in seminal work conducted by Greenstein and Siegal (1998).
Representation of adherence dimensions will be captured through use of the self-report Basel
Assessment of Adherence to Immunosuppressive Medication Scale (BAASIS) and examination
of specific beliefs regarding IST medications using the Beliefs about Medicines questionnaire.
Three areas represented in the model will not be explored in this study. First, health
outcomes associated with adherence behaviors including acute rejection, late acute rejection, and
graft failure will not be explored within the context of this study as examination of these
outcomes exceeds the proposed study purpose and design. Second, health decisions, or the
process by which individuals make decisions that influence adherence will not be explored in
this study. The decision to undergo transplantation as a treatment for end stage renal disease
involves a decision making process that includes evaluating the lifelong therapy necessary to
sustain the transplant. Given the long-term posttransplant sample population selected for study,
key decisions related to adherence behaviors are assumed to have already occurred. Lastly,
knowledge as it relates to IST interventions will not be explored. It was a study assumption that
long-term participants would already possess the necessary knowledge regarding IST
medications acquired through both pretransplant education and acute posttransplant care and
follow-up.
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Figure 1 depicts adaptations to the Health Decision Model reflective of this study. Figure
2 illustrates the adapted model that served as a guide for this study.

Adapted from “Understanding and Improving Patient Compliance” by Stephen A. Eraker and John P. Kirscht,
1984, Annals of Internal Medicine, 100, p.261

Figure 1 Health Decision Model
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Figure 2: Adapted Health Decision Model
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Summary
This chapter has presented the current state of the knowledge regarding
immunosuppressant adherence in renal transplant recipients, issues with definition and
measurement, and variables that impact optimum IST adherence. Strengths of the literature
review are that much research has been conducted on IST adherence in renal transplant recipients
since the early 1990’s. Studies exploring the impact of nonadherence on acute and late acute
rejection and graft loss have noted the influence on outcomes and propelled further research
studies focused on identifying contributing factors. Additional studies exploring the impact of
categories of influencing factors (socioeconomic, patient-related, condition-related, therapy
related, and healthcare system / healthcare team-related factors) have led to predictive models
and profiles that have identified variables amenable to intervention.
While strengths in the literature review were evident, weaknesses emerged. Given the
focus on improving long-term outcomes, no study was identified that focused on exploring
contributing factors in a population of long-term recipients. While many study populations
included recipients that were several years from transplant, many studies included recipients as
early as six months from transplant. In addition, immunosuppressive regimens have evolved
over time potentially altering the symptom experience and complexity of dosing regimens.
Finally, given the continued evidence surrounding the limitations of all methods of measuring
medication adherence, only a few studies have explored the phenomenon using a combination of
methods suggested to better represent the prevalence of adherence. This research study will add
to the current state of knowledge by exploring factors known to influence IST adherence in a
population of long-term renal transplant recipients helping to understand if the same factors
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known to influence adherence in previous studies are the same or different in long-term
recipients. Findings could identify modifiable factors amenable to interventions that could
sustain or improve long-term IST adherence.
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CHAPTER THREE: METHODS
The purpose of this study was to examine demographic variables, time since transplant,
immunosuppressive agents, health beliefs, symptom experience, and social support and test their
effect on IST adherence in a population of long-term adult renal transplants as predicted by the
Health Decision Model (Eraker, Kirscht, & Becker, 1984).
Design
A cross-sectional, correlational design was used in this study to collect data at a single
point in time using a voluntary convenience sample. This design was chosen to understand the
relationships between the predictor variables of demographics, time since transplant,
immunosuppressive agents, health beliefs, self-efficacy, symptom experience and social support
and test their effect on the outcome variable of IST adherence in adult renal transplant recipients.
Sample
The study population consisted of a convenience sample of eligible adult renal transplant
recipients who were three years or more from transplant and due to attend their annual transplant
clinic appointment. The sample was obtained from patients receiving care at a large transplant
center that met inclusion criteria and gave consent. Demographic data obtained at enrollment
was used to validate meeting inclusion criteria.
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Inclusion/Exclusion Criteria

To be included in the proposed study, sample participants must have been > 21 years of
age at the time of initial transplant; single kidney transplant recipient; able to speak, read, and
understand the English language; had a functioning graft at the time of the study; and be three
years or more from initial transplant. Graft function was determined by measured serum
creatinine levels. A serum creatinine of 0.6-1.2 mg / dL from the clinic laboratory was
considered normal range. Serum creatinine values obtained from outside laboratories were
evaluated using reference values established by the transplant clinic laboratory. Transplant
recipients with elevated serum creatinine levels were included in the study if the level was within
the patient’s maintenance baseline as determined by the transplant clinic provider.
Participants were excluded from the study if the elevated serum creatinine was not within
the patient’s maintenance baseline or if the participant had been retransplanted. Due to a lack of
studies validating instruments in languages other than English, participants that did not speak,
read or understand the English language were excluded from the study.
Determination of Sample Size
Power Analysis
An a priori power analysis was calculated by means of G*Power 3.0.8 (Faul, Erdfelder,
Lang & Bucher, 2007) to determine the required sample size given a level of significance (α =
.05), power of .80 (β = 0.20) and medium effect size (0.15) for linear multiple regression. Effect
size was set as medium (Cohen, 1999) as the literature review was unable to provide a consistent
estimate.
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The primary research question contained six independent variables which were examined
for relationships to the outcome variable of IST adherence. Statistical analyses planned included
chi-square, Spearman correlation, independent-samples t test, and logistic regression. For
logistic regression analysis with six predictor variables, anticipating a medium effect size (0.15),
a sample of 98 was necessary. The sample size of 98 was further supported with
recommendations for a ratio of subjects to independent variables of at least 15 :1 (Mertler &
Vanatta, 2005; Tabachnick & Fidell, 2007), which was a minimum of 90 subjects.
Setting
The site selected for the conduct of this study was Florida Hospital Transplant Clinic, a
single site outpatient transplant clinic, in operation since 1973 and located in a large urban
community in the Southeastern region of the United States. Since 1988, a total of 2,686 kidney
transplants (living related-567; deceased donor-2119), procedures were performed across ethnic
categories (White, Black, Hispanic, Asian, American Indian/Alaska Native, Pacific Islander,
Multiracial) in the acute care facility associated with the outpatient clinic (Organ Procurement
Transplant Network [OPTN], 2011). The site was selected due to the length of time in operation,
the size of the recipient database, the scope of transplant services provided by the clinic, and the
potential representation of the sample population.
Following completion of the acute care phase after renal transplantation provided by the
Florida Hospital Transplant Clinic, primary care of the transplant recipient shifted to the local
nephrologist for long-term care. Long-term follow-up care included monthly visits with the
recipient’s local nephrologist for the first year followed by every 2-3 months thereafter.
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In addition to care provided by the local nephrologist, Florida Hospital Transplant Clinic
followed the patient every 6 months during the first year posttransplant and annually thereafter.
Immunosuppressive agents prescribed by providers at the clinic included tacrolimus (Prograf),
sirolimus (Rapamune), cyclosporine (Neoral), mycophenolate mofetil (Cellcept), mycophenolate
sodium (Myfortic), and prednisone. The primary IST regimen used included tacrolimus
(Prograf) in combination with either mycophenolate mofetil (Cellcept) or mycophenolate sodium
(Myfortic) with or without prednisone. If prednisone was a part of the IST regimen at 6 months
posttransplant, doses were reduced monthly to a final dose of 5 mg/ day. Therapeutic monitoring
of IST regimens included serum trough levels of tacrolimus (Prograf) and/or sirolimus
(Rapamune) drawn within one week of the recipient’s scheduled appointment if drawn at an
outside lab or the day of the appointment if drawn at the Transplant Clinic lab. Therapeutic drug
monitoring of mycophenolate mofetil (CellCept) and mycophenolate sodium (Myfortic) was not
performed at this site. Dosage adjustments of Cellcept and/or Myfortic occurred only in the
presence of adverse clinic effects (persistent, severe diarrhea, severe leukopenia < 2.0) and after
consultation with clinic providers.
Approximately 30-45 patients were seen monthly for annual transplant follow-up
evaluation. It was estimated that 10 patients per month would meet study inclusion criteria.
The data collection period began July 2010 and concluded September 2011 with a total of 98
participants enrolled. Figure 3 provides an enrollment summary.
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113 Patients assessed for initial eligibility criteria

3 Refused
7 Missed*

103 Consented participants
5 Did not meet final inclusion criteria

98 Met final inclusion criteria

98 Enrolled

98 Final enrolled participants included in analysis

*Missed = cancelled appointment, no-show for scheduled appointment, or missed by PI
Figure 3: Enrollment Summary
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Ethical Considerations
Protection of Human Subjects
Protection of study participants was accomplished by adhering to ethical and legal
guidelines. All policies for protection of human subjects mandated by the institutional review
boards of the University of Central Florida and Florida Hospital, and United States Federal
Guidelines for conducting research with human subjects (U.S. Department of Health and Human
Services (DHHS), 2001) were followed. Authorization to access individually identifiable health
information was accomplished by having study participants sign a HIPAA Privacy Authorization
form which was part of the informed consent process.
Informing Participants

The study was approved by the Institutional Review Boards of both Florida Hospital and
the University of Central Florida (see Appendix H). Informed consent was obtained by the
principal investigator.
Protecting Respondents
Individual responses to study instruments were anonymous; no identifying information,
such as name or address was collected. Confidentiality was accomplished by assigning each
participant a five digit study identification number which eliminated the discovery of any
personal information. The created identification number was not linked to any personal medical
record number or personal identifying data, and was used for all data. Only the researcher and
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her research supervisor had access to the data files which were stored in a password protected
computer.
Risks and Benefits to Participants
While there were no anticipated risks involved in participating it was possible that a
participant could experience minor psychological discomfort when disclosing both symptom
experiences as well as adherence behaviors. There were no direct benefits to participants aside
from helping healthcare providers gain an understanding of factors that contribute to long-term
IST adherence.
Data Collection
Sampling Procedure
Recruitment of participants was facilitated through use of the transplant center’s recipient
database. The transplant clinic coordinator in charge of scheduling annual follow-up
appointments provided a weekly list of the number of potential participants meeting initial study
inclusion criteria (age> 21, single transplant, and 3 or more years from initial transplant) to the
principal investigator. The list provided to the principal investigator included only the date and
time of the potential participant’s annual clinic appointment. Initial interest in study participation
was determined upon arrival of the potential participant for the annual visit and was facilitated
by clinic staff. Recipients expressing an initial interest in study participation were approached
by the principal investigator to obtain informed consent, and then screened for final study
inclusion criteria (serum creatinine, English language skills). To enhance recruitment, a flyer
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advertising the study was posted in the transplant clinic waiting room (see Appendix A). At
month 12, initial study inclusion criteria was amended to exclude eligible participants previously
enrolled in this study during the past year to avoid studying the same subjects twice.
Data Collection Process
Data collection was conducted by the principal investigator who was unknown to study
participants and was not a member of the outpatient transplant clinic staff. Medical data (serum
creatinine levels and serum drug assays) were obtained through a review of each participant’s
medical record conducted following the informed consent process. Medical data reviewed
included serum creatinine and serum drug assay results as reported on the day of the participant’s
evaluation. The majority of participants had lab drawn in the clinic lab, a Clinical Laboratory
Improvement Amendments (CLIA) certified lab. For participants with insurance designated
requirements to use independent selected labs, only specimens drawn within the week prior to
the annual clinic appointment were accepted.
All study instruments were administered by the principal investigator using an interview
format in the private examination room located within the outpatient transplant clinic. The
average wait time for clinic appointments was approximately 30-60 minutes for patients
requiring laboratory services, and 15-30 minutes for patients not requiring laboratory services.
Based on the identified time intervals, all potential participants underwent final screening and
consenting immediately prior to their clinic appointment. If time permitted, all study instruments
were administered prior the participant’s medical visit. Participants were presented study
instruments in the following sequence: 1) demographic survey, 2) the Beliefs About Medicines
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Questionnaire (BMQ) (Horne, Weinman, & Hankins, 1999), 3) the Medical Outcomes Study
(MOS) Modified Social Support Survey (MSSS) (Ritvo, Fischer, Miller, Andrews, Paty, &
LaRocca, 1997), 4) the Basel Assessment of Adherence with Immunosuppressive Medication
Scales (BAASIS) (De Geest, 2005), and 5) the Modified Transplant Symptom Occurrence and
Symptom Distress Scale-59R (MTSOSD-59R) (Dobbels, Moons, Abraham, Larsen, Dupont, &
De Geest, 2008). All instruments were administered in computer format using Survey
Monkey™ (http://www.surveymonkey.com/). Use of the computerized methods for data
collection were piloted with the first 5 subjects who found it acceptable. In addition to the
instruments completed by study participants, a collateral assessment of adherence was completed
by one transplant clinic registered nurse and the attending transplant clinic physician or nurse
practitioner at the conclusion of the participant’s examination.
In the event the participant declined use of the computer, or was unable to operate a
computer, paper instruments were made available to the participant. Data obtained from paper
instruments were entered into the Survey Monkey™ file by the principal investigator, with each
survey item double checked for accuracy.
Approximately one hour was allotted during the participant’s clinic appointment for
instrument completion. All instruments completed on paper were examined for missing items
prior to the participant leaving the study session. Participants were compensated with a $25.00
gift card at the end of data collection.
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Data Collection Procedures
All study data recorded in the Survey Monkey™ program was downloaded by the
principal investigator into a Microsoft Excel spreadsheet, and imported into the Statistical
Package for the Social Sciences (SPSS) for Windows v 19.0 (SPSS, Inc., 2010) for statistical
analysis. No errors in data entry were identified. Figure 4 summarizes study data collection
processes and procedures.
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Clinic Staff Screen Scheduled
Participants for Initial Study Inclusion
Criteria:
*> 21 years of age
* > 3 years posttransplant
primary/single renal transplant

Eligible Participant Consented
by Principal Investigator

Principal Investigator Screens
for Final Study Inclusion
Criteria

Final Study Inclusion Criteria:
*normal or maintenance baseline
serum creatinine
*able to speak, read English
language

Participant Completion of
Instruments: Demographic,
BMQ, MSSS, BAASIS,
MTSOSD-59R

Copy of Consent/Gift Card
To Participant

Figure 4: Data Collection Processes and Procedures
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Investigator Completion of
Investigator Demographic;
Clinician Collateral Reports

Data Storage
Access to study data was limited to the principal investigator and the chair of her
dissertation committee. Once downloaded to the principal investigator’s password protected
computer, all data were backed up onto a compact disk (CD) and stored in a locked file cabinet
in the principal investigator’s office. At the end of a five year time frame, the CD and any other
research materials will be destroyed.
Pilot Study
A pilot study was conducted on the first 5 participants for the following purposes: 1)
testing the feasibility of study instruments, 2) determining clarity of instrument instructions, 3)
obtaining an average estimation of instrument completion time, and 4) evaluating potential for
interruptions in transplant clinic work flow. Data obtained from pilot study participants were
included in the analysis as no instrument modifications were made. One minor modification was
made to the study protocol allowing for administration of all study instruments prior to the
participant’s clinic appointment if time allowed.
Instrumentation
In addition to demographic information, participants completed the following data
collection instruments: 1) Beliefs About Medicines Questionnaire (BMQ); 2) Medical Outcomes
Study (MOS) Modified Social Support Scale (MSSS), 3) Basel Assessment of Adherence with
Immunosuppressive Medication Scale (BAASIS), and 4) the Modified Transplant Symptom
Occurrence and Symptom Distress Scale-59R (MTSOSD-59R) (see Appendix D). Each of
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these measures demonstrated reliability and or validity either within the adult renal transplant or
chronic illness populations. In addition, all measures had the same recall period of four weeks to
reduce the potential for recall bias. Measures not evaluated previously evaluated within the adult
renal population were tested for internal consistency reliability by means of Cronbach’s alpha
(α).
Demographic Survey

Demographic variables were collected using both participant and investigator collected
instruments developed specifically for the study. All participant demographic variables were
defined using categories as delineated by the Organ Procurement Transplant Network (2011)
and/or the United States Census Bureau (2010).
Select demographic variables were calculated: age, time postttransplant, and the IST
medication complexity index. Age at the time of study and time posttransplant were calculated
and reported in years using birthdate, transplant date, and date of enrollment. Complexity of IST
regimen was represented by a complexity index score calculated as the product of the number of
IST medications in the regimen, the number of pills taken per day, and the number of times per
day IST medications were taken.
Serum creatinine, as reported the day of enrollment, was obtained from the medical
record. Serum creatinine values from all laboratory sources were evaluated using transplant
clinic normal values (0.6-1.2 mg / dL) consistent with provider practice.
Serum drug assays were evaluated according to target therapeutic values determined by
the transplant clinic for recipients beyond the sixth month from transplantation. These values
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include: tacrolimus: 5-10 mg/L; sirolimus: 8-15 mg/L; and cyclosporine 150-250 mg/L.
Therapeutic monitoring for mycophenolate mofetil (CellCept) and mycophenolate sodium
(Myfortic) was not conducted at this facility.
Beliefs About Medicines Questionnaire
The Beliefs about Medicines Questionnaire (BMQ) constructed and tested by Horne,
Weinman, and Hankins (1999) is composed of two sections: BMQ Specific and BMQ General.
The BMQ Specific is further divided into two five-item subscales: Specific Necessity assessing a
patient’s beliefs about the necessity of prescribed medications, and the Specific Concerns
assessing concerns about consequences of taking the same medications. The BMQ General
section, which include the General Harms subscale and General Overuse subscale, assesses
beliefs held by patients that often seek alternative methods of treatment such as herbal treatments
or care from a homeopathic clinic (Horne et al., 1999). This section of the instrument was not
applicable to the population under study and therefore was not used.
Validity
As part of instrument development, Horne et al (1999) established construct validity of
instrument scales by performing exploratory principal component analysis. Scale items were
derived from a pool of 34 items representing commonly held beliefs identified in the literature
about medication. Data were based on a sample of 524 patients encompassing a variety of
chronic illness categories (asthma n=78, diabetic n=99, renal n=47, psychiatric n=89, cardiac
n=120, general medical n=91). Confirmatory factor analysis was conducted to verify the factor
structure. Pearson correlation of items with predicted factor pattern yielded 0.88 for BMQ
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Specific Necessity subscale and a 0.88 for the BMQ Specific Concerns subscale within the renal
dialysis subsample.
Psychometric evaluation of the instrument provided evidence of both criterion-related
and discriminant validity (Horne, Weinman, & Hankins, 1999). Criterion related validity was
based on a two predictions: 1) that patients with stronger beliefs in the necessity of medication
would be less likely to believe they can cope without medication (Specific Necessity subscale),
and 2) that patients with strong concerns about prescribed medication who were more distrustful,
would require more information about medication and would be more likely to change their
current treatment regimen (Horne et al, 1999). Evidence for criterion-related validity was
demonstrated with a negative correlation between scale scores and responses to the belief that
they could cope without medicine (Specific Necessity, p<.001)) and a positive correlation
between scale scores and the belief that they could not always trust medications (Specific
Concerns, p<.005).
Discriminant validity was tested on the ability of the instrument to distinguish between
different illness and treatment modalities. Testing hypothesized that beliefs about the necessity
of medications would be influenced by the type of treatment for a specified illness (Specific
Necessity) and Specific Concern scores would differentiate between different diagnostic groups
with concerns varying based upon illness category. Predictions were confirmed by significantly
higher Specific Concern scores for identified groups.
Reliability
Cronbach’s alpha values for the renal dialysis diagnostic group established internal
consistency of 0.55 for Specific Necessity and 0.73 for Specific Concerns. A study conducted
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with the human immunodeficiency virus (HIV) population investigating beliefs associated with
nonadherence to antiviral therapy identified internal reliability of both BMQ scales with
Cronbach’s alpha of 0.80 for Specific Necessity, and 0.82 for Specific Concerns (Horne, Buick,
Fisher, Leake, Cooper, & Weinman, 2004).
While the BMQ has been used in a study conducted within the renal transplant population
(Butler et al., 2004), no additional information specific to the validity and reliability of the
instrument in the study was provided.
Scoring
Subscale items are measured using a five point Likert scale with one being “strongly
disagree” and five “strongly agree.” Possible scores for each subscale range from a minimum of
five to a maximum of 25, with higher scores indicating stronger beliefs. A mean score for each
subscale of the BMQ Specific was calculated by dividing the total scale score by the total
number of items. The mean item score for each subscale was used to calculate a necessityconcerns differential (NCD) which was obtained by subtracting the Specific Concerns mean
score from the Specific Necessity mean score providing a numerical indicator of the way an
individual rates the need for medications to concerns over taking medications. A negative NCD
value indicated an individual rated concern over taking medications higher than the beliefs about
the necessity for taking medications.
Medical Outcomes Study Modified Social Support Scale
The Medical Outcomes Study (MOS) Modified Social Support Survey (MSSS) is a
modified version of the Medical Outcomes Study Social Support Survey developed and tested by

49

Sherbourne and Stewart (1991). The 18 item MOS Modified Social Support Scale, one of ten
subscales modified for use within the Multiple Sclerosis Quality of Life Inventory (MSQLI),
measures perceived availability of various components of functional support (see Appendix K).
Within the 18 items are four subscales representing multiple dimensions of social support. Four
items (1,4,11,13) measure tangible support, eight items measure emotional/informational support
(2,3,7,8,12,14,15,17), three items measure affectionate support (5,9,18), and three items measure
positive social interaction (6,10,16). A five item version of the MOS MSSS is also available
(MSSS-5) and consists of the 5 items (items 4, 6, 9, 11, and 17) that correlate most strongly with
the total MSSS scale with all four subscales represented. The 18 item instrument was selected
for use in this study due to the limited number of recent studies exploring social support within
the renal transplant population.
Validity
Factorial validity, discriminant validity, and construct validity were established for the
original Medical Outcomes (MOS) Study Social Support Survey by Sherbourne and Stewart
(1991). Using responses from 2987 subjects, factor analysis discriminated four dimensions of
social support: emotional / informational, tangible, affectionate, and positive social interaction.
Confirmatory factor analysis of the original 19 items produced high correlations between
emotional and informational support (0.99) while principal components factor analysis of the 19
original items show high loadings for all items ranging from 0.67-0.88. Discriminant validity
was supported as single-item measures of structural support were distinct from functional
support concepts. All items in the four subscales correlated higher with their own scale than
with any other social support measure. All items exceeded convergent validity criteria with item
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correlations ranging between 0.72-0.87 for tangible support, 0.80-0.86 for the affection scale,
0.82-0.90 for the emotional / information scale, and 0.87-0.88 for the positive interaction scale
(Sherbourne & Stewart, 1991).
Confirmatory factory analysis of the original 18-item scale as well as two abbreviated
versions was performed in a study of 330 mothers with a child in mental health treatment
(Gjesfjeld, Greeno, & Kim, 2009). Both the twelve and four item scales demonstrates the best fit
with reported Goodness of Fit Indices of .95 and1.00 respectively.
Reliability
Sherbourne and Stewart (1991) established internal-consistency reliability of scale scores
using Cronbach’s alpha. Pearson Product Moment correlations between support measures at
enrollment and the same measures one year later estimated one year stability coefficients.
Analysis performed for the Medical Outcomes Study sample found emotional/ informational
support, tangible support, positive social interaction, and affectionate support correlations ranged
between 0.91-.0.96. One year stability coefficients ranged between .72-.78 across all subscales
(Sherbourne & Stewart, 1991).
The Consortium of Multiple Sclerosis Centers Health Services Research Committee in its
construction of the Multiple Sclerosis Quality of Life Inventory (National Multiple Sclerosis
Society, 1997), created the 18 item Modified Social Support Survey as one of 10 subscales used
to measure health-related quality of life in multiple sclerosis patients. Analysis yielded
Cronbach’s alpha for tangible support, emotional support, affective support, and positive
interaction support ranging between 0.87 and 0.85. The same Consortium reported a Cronbach’s
alpha of 0.88 for the abbreviated 5 item version of the MOS-MSSS scale.
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To date, one study conducted within the adult renal transplant population (ChisholmBurns, Spivey, & Wilks, 2009) has used the 5 item version of the MOS-MSSS scale; however
validity and reliability statistics were not reported.
Scoring
Each of the 18 items are measured on a 5-point Likert scale (1= none of the time to 5= all
of the time). The MSSS yields 4 subscale scores (Tangible Support [TAN], Emotional /
Informational Support [EMI], Affectionate Support [AFF], and Positive Social Interaction
[POS]. Raw scores range as follows for each subscale: 1) TAN 4-20; 2) EMI 8-40; 3) AFF 315; and 4) POS 3-15. Higher scale scores indicate greater perceived support.
Modified Transplant Symptom Occurrence and Symptom Distress Scale
The Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD59R), was developed as an updated and validated version of the 45 item Modified Transplant
Symptom Occurrence and Symptom Distress Scale (Moons, De Geest, Versteven, Abraham,
Vlamick, Moens, & Waer, 2001) to reflect the transplant patient’s symptom experience with
currently available immunosuppressive regimens (see Appendix K). The 59 item scale assesses
symptom frequency and symptom distress associated with the use of current immunosuppressive
agents (cyclosporine, corticosteroids, azathioprine, tacrolimus, mycophenolic-acid containing
formulations, mTOR inhibitors and belatacept) (Dobbels et al., 2008).
Validity
To establish content validity, new items generated on the updated scale were added
following a comprehensive review of the literature and analysis of adverse event forms of
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belatacept studies, yielding a total of 76 items. A panel of 21 experts reviewed all items. Expert
feedback resulted in the current 59-item version. Discriminant validity of the scale was tested in
a pilot study of 24 adult renal transplant patients and 84 lung transplant patients (Dobbels et al.,
2008). Discriminant validity was supported noting symptom profiles differed significantly with
females demonstrating a higher symptom occurrence (p =0.096) and significantly higher
symptom distress (p=0.017). In addition, patients with depressive symptoms had a significantly
higher symptom occurrence (P=.030) and higher symptom distress (p=.006) compared to patients
without depressive symptoms (Dobbels et al. 2008).
Reliability
An earlier study conducted for the purpose of establishing psychometric properties of the
29 item MTSOSD scale concluded that internal consistency assessment of the scale was neither
useful or allowed (Moons, De Geest, Versteven, Abraham, Vlamick, Moens, & Waer, 2001).
This finding was due to the presence of negative correlations in the correlation matrix which
indicated symptoms were not correlated unidirectionally, violating a key assumption for the
calculation of Cronbach’s alpha. As such, internal consistency was not reported in this study.
To date, the MTSOSD-59R has been used in one study conducted within the adult renal
transplant population exploring distress associated with adverse effects of IST medication
(Koller et al. 2010). No additional information specific to the validity of the instrument in the
study was provided.
Scoring
Symptom occurrence and symptom distress are scored on a 5- point Likert scale (0 =
never occurring to 4 = always occurring; 0= not at all distressing to 4= terribly distressing).
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Each item is a symptom scored in view of both symptom frequency of occurrence and symptom
distress. In this study and consistent with previous research, ridit analysis, a statistical method
used for analysis of ordinal level data (Delesis & Sermeus, 1996), was used to rank symptom
occurrence and symptom distress items. Ridit scores range from a minimum of 0 to a maximum
of 1. A ridit score of 0.5 represents equal probability, while ridit scores of > 0.5 represents
higher probability. For the calculation of individual symptom distress ridits, symptoms reported
as never occurring were coded as “missing data” and excluded from analysis to be truly
representative of the symptoms they had. For final analysis, total individual participant symptom
occurrence and symptom distress ridit scores were calculated as the sum of all individual item
ridit values for each scale (symptom occurrence and symptom distress).
Basel Assessment of Adherence with Immunosuppressive Medication Scale
Developed by the Leuven-Basel Adherence Research Group (2005) to assess recent IST
adherence (previous 4 weeks) in adult renal transplant recipients, the four item Basel Assessment
of Adherence with Immunosuppressive Medication Scale (BAASIS) was conceptualized based
on the dimensions of medication taking adherence (taking, timing, omitting / drug holidays, dose
reduction). While there is a measure of IST adherence with demonstrated validity and reliability
in the adult renal transplant population available (Immunosuppressant Therapy Adherence Scale
[ITAS]), the BAASIS instrument was used for this study. Selection of this tool was based on
more clearly defined scoring categories (0=never to 5=everyday BAASIS; 0%=none to > 50% =
very frequent ITAS) as well as more recent recall of nonadherence (4 weeks-BAASIS; 3 monthsITAS) consistent with other instruments to be used in this study.
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Validity
Early validation of the instrument has been reported in both the renal transplant
population as well as the HIV population. In the adult renal transplant population, all four items
of the BAASIS scale had superior sensitivity in detecting nonadherence compared with the
Siegal Scale (Schäfer et al., work in progress of the Leuven-Basel Adherence Research Group).
A study conducted within the HIV population demonstrated validity of the scale as a strong
linear relationship was found between the number of missed doses and optimal viral suppression
with the test for linear trend highly significant (p < 0.0001) (Glass, De Geest, Weber, Vernazza,
Rickenbach et al., 2006).
Reliability
Internal consistency, as a measure of reliability of the BAASIS has not yet been
established within the transplant population.
To date, the BAASIS instrument has been used in only one study conducted within the
renal transplant population (Schmid-Mohler et al., 2010). No information specific to the validity
and reliability of the instrument in the study was provided.
Scoring
Responses are scored on a 6 point Likert scale (0 = never to 5 = everyday). For the
purpose of this study, nonadherence was defined as any self-reported nonadherence (response
score 1 to 5) on any of the four items. Consistent with current research (Schmid-Mohler, 2009),
taking adherence scores were dichotomized as “adherent” (0) and “nonadherent (1-5), and
timing non-adherence scores were classified ordinally as “adherent” (0), “partial adherent” (1-2)
and “nonadherent” (3-5).
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Composite Score of Adherence
Current literature supports the use of a combination of adherence measures to increase
the diagnostic accuracy of assessing adherence (Schäfer-Keller, Steiger, Bock, Denhaerynck, &
De Geest, 2008).
Validity
Two composite adherence scores (CAS) were evaluated for validity. Composite
adherence score 2 (CAS 2) which consists of a self- report of adherence, collateral reports of
adherence, and nontherapeutic blood assay viability demonstrated the highest sensitivity
(72.1%), followed by composite adherence score 1 (CAS1) (62.8%), validating both as
acceptable screening measures for IST adherence (Schäfer-Keller et al., 2008). In the same
study, validation of the different methods comprising the composite score identified the
following: 1) non-therapeutic assay variability and self-reported nonadherence were found to
correlate significantly (p< .05); 2) self-reported nonadherence correlated significantly with
measures captured through electronic monitoring methods (p< .05); 3) clinician collateral reports
significantly correlated with electronic monitoring dosing and taking adherence (p< .05); 4)
CAS 1 correlated significantly with taking and timing adherence as well as non-therapeutic
blood assay variability (ranging from r rho = 0.129 [p<.05] to r rho = 0.333 [p<.05]); and 5) CAS 2
(patient self-reported adherence, clinician collateral report of adherence, and nontherapeutic
blood assay variability) correlated significantly with electronic monitoring drug holidays ,
dosing, taking, and timing adherence (ranging from r rho =0.135 [p<.05] to r rho =0.289 [p<.05])
(Schäfer-Keller et al., 2008).
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Composite Score of Adherence Components
BAASIS
For use as the self-report component of the final CAS score, a total BAASIS score was
calculated as the sum of response scores to the four scale items. Any self-reported nonadherence
on any of the instruments four items classified the participant as nonadherent. For final analysis
as a component of the CAS score, the total BAASIS score was dichotomized (adherent,
nonadherent), reverse scored, and coded in SPSS as “0”= nonadherent and “1” = adherent.
Collateral Report of Adherence
Collaterally reported adherence, defined as a method of providing information about a
patient’s medication taking behavior as reported by a third party (De Geest, Abraham, &
Dunbar-Jacob, 1996), was measured using two reports: one provided by the transplant clinic
registered nurse, and one by the attending transplant clinic provider (physician or nurse
practitioner) (see Appendix K). Clinicians were asked to rate the participant’s overall general
immunosuppressant adherence as “good” (0), “fair” (1), or “poor (2)”. Consistent with previous
research (Schmid-Mohler et al., 2009), clinician collateral responses were combined and scored
as “adherent” (both clinician’s estimated “good”), “partially adherent” (one clinician estimated
“fair” or “poor”), and “nonadherent” (both clinicians estimated “poor”). Total combined scores
ranged from 0-4 (0 = “adherent”, 1-3 “partially adherent”, 4 = “nonadherent”). For final analysis
as a component of the composite adherence score (CAS) total collateral report of adherence
scores were dichotomized (adherent / nonadherent), and coded in SPSS as “0”= nonadherent, and
“1” = adherent.
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Nontherapeutic Blood Assay
Serum drug assay was assessed using a single serum trough level for the monitored IST
agent. A therapeutic drug range was specified for each immunosuppressive agent based on
clinical guidelines used at the selected study site. Therapeutic ranges were defined as
follows: tacrolimus (Prograf), 5-10 ng / mL; sirolimus (Rapamune), 8-15 ng / mL; and
cyclosporine (Sandimmune), 15-250 ng /mL. Mycophenolate mofetil (Cellcept) and
mycophenolate sodium (Myfortic) therapeutic assays were not currently monitored at the study
site. Serum drug assays were scored as “adherent” (0) if assessed value was within therapeutic
range, and “nonadherent” (1) if outside normal range. For final analysis as a component of the
composite adherence score (CAS) serum drug assays scores were dichotomized (adherent /
nonadherent), and coded in SPSS as “0”= nonadherent, and “1” = adherent.
CAS Scoring
For final analysis, the composite adherence score (CAS) was calculated and consisted of
a self-report measure of adherence ( BAASIS), two clinician collateral reports of adherence, and
a single serum IST medication trough level. Consistent with the literature, cut-off criteria for
nonadherence consisted of self-reported nonadherence, and / or at least 1 clinician’s response of
“fair” or lower adherence, and / or non-therapeutic drug assay (Schäfer-Keller et al., 2008). The
sum of the dichotomized scores for the BAASIS, clinician collateral reports, and serum drug
trough level were totaled. Final CAS cut score was coded in SPSS as “0”= nonadherent, and “1”
= adherent.
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Statistical Analysis
Data were analyzed using Statistical Package for the Social Sciences (SPSS; version
19.0).

All data were prescreened prior to analysis by exploring descriptive statistics,

characteristics of distribution (central tendency, variability, skewness, kurtosis), and for the
presence of missing values and outliers. Depending upon the level of measurement and
distribution of each variable, data were expressed in frequencies or means and standard
deviations. Spearman correlation coefficients were calculated to determine the strength of the
relationship between independent predictor variables and the dependent outcome variable of
adherence. Independent-samples t tests were used for two group comparisons of continuous
variables. A significance level of < .05 was considered statistically significant.
To answer the primary research question, logistic regression was performed. For logistic
regression, the model fit, classification table, and summary of model variables were evaluated to
determine the accuracy of the developed regression model.
Statistical Assumptions
Descriptive statistics were computed for all variables. Data were explored to evaluate
normality of distribution and homogeneity of variance. Distributions were evaluated by means
of histograms, skewness and kurtosis, and the Kolmogorov-Smirnov (D) statistic. Data from
different participants were independent and not influenced by the behavior of other participants.
Nonparametric tests were performed for those variables not meeting assumptions of normality
and for determining the strength of the relationship between variables measured at the ordinal
level. Parametric tests identified as robust and tolerant of violations of assumption of normality
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were performed to compare means across groups. Homogeneity of variance was assessed using
Levene’s test (Mertler & Vanatta, 2005).
Prior to logistic regression analysis, data were prescreened for outliers, and predictor
variables were evaluated for multicollinearity. Goodness-of-fit test was performed to assess the
fit of the model to the data.
Quality Control
All data were prescreened and evaluated for missing values and outliers. Missing values
were minimal and were replaced with the mean or mode of the population depending upon the
level of variable measure. Outliers were identified by inspection of box plots. Outliers were
included in analysis using nonparametric tests as these tests are less sensitive to the effects of
outliers. Outliers were included in analysis using robust parametric tests that are tolerant of
violations of normality produced by the effects of outliers.
Hypothesis Testing
Univariate analysis was performed to assess the relationship between all demographic
variables, BMQ, MSSS, and MTSOSD-59R ridit scores and the outcome variable of adherence.
All independent variables demonstrating a significant relationship to the dependent variable were
entered into the final logistic regression analysis.
In addition to the primary research question, ten hypotheses were tested. Hypothesis 1, 2,
3, 5, 7, and 9 examined the relationship between one predictor variable and the outcome variable
of composite adherence group classification. Given the ordinal level of measure of the
dependent variable, these hypotheses were tested using Spearman’s correlation coefficient.
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Hypothesis 4, 6, 8, and 10 explored differences in variable scale scores between composite
adherence group classifications. Analysis was performed using independent-samples t test due
its robust nature in tolerating violations of the assumption of normality. Independent-samples t
tests were also used in to assess differences in scores of variable scales between age, gender, and
time posttransplant groups.
Spearman Correlation Coefficient
Spearman correlation coefficient examines the strength of the relationship between two
variables.
H 1: There will be a significant negative relationship between the predictor variable of
time posttransplant as measured in years and composite adherence score classification.
H 2: There will be a significant relationship between the predictor variable of age as
as measured in years and composite adherence classification.
H 3: There will be a significant relationship between medication complexity index scores
and composite adherence group classifications.
H 5: There will be a significant relationship between the predictor variable of health
beliefs as measured by BMQ Necessity and BMQ Concerns scores and composite adherence
group classification.
H 7: There will be a significant positive relationship between the predictor variable of
social support as measured by MSSS subscale and total scale scores and composite adherence
group classification.
H 9: There will be a significant negative relationship between the predictor variable of
symptom experience as measured by MTSOSD-59R total ridit scores and composite adherence
group classification.
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Independent-Samples t Test
Independent-samples t test compares the means of two samples. While scores should be
normally distributed, the test is robust and can handle violations of the assumption of normality.
H 4: There will be a significant difference in IST complexity index scores between
composite adherence group classifications.
H 6: There will be a significant difference in BMQ Necessity subscale, BMQ Concerns
subscale, and BMQ Necessity / Concerns differential scores between composite adherence group
classifications.
H 8: There will be a significant difference in MSSS subscale and total scale scores
between composite adherence group classifications.
H 10: There will be a significant difference in MTSOSD-59R total ridit scores between
composite adherence group classifications.
Logistic Regression
Logistic regression seeks to identify which combination of independent variables best
predicts membership into groups.
Primary research question: which of six predictor variables-demographic variables, time
since transplant, immunosuppressive agents, health beliefs, social support, and symptom
experience-are most influential in predicting IST adherence in long-term adult renal transplant
recipients?
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Methodological Limitations
Methodological limitations identified in the current study are related to issues with
design, sampling, measurement, and statistical analysis.
Design
Use of a cross sectional, correlational design isolates exploration of the continuum of
nonadherence to one point in time. Many researchers in the field hold the belief that
nonadherence is not an isolated phenomena but rather a dynamic phenomenon that exists on a
continuum, changing over time, with all patients most likely demonstrating nonadherence
behavior at any given time. Within the context of this study, the design limits the assessment of
nonadherence to one point in time.
Sampling
Use of a convenience sampling plan is not without limitations. Consistent with
nonprobability methods, there is potential for systematic over or under-representation of
population elements. As a result, the sample obtained for this study may not be representative
of the target population limiting generalizability of findings. Additional potential for bias exists
due to the likelihood that adherent participants presenting for annual follow-up are more likely to
adhere to all aspects of a treatment plan including appointments.
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Measurement
While a combination of methods was used to measure adherence, each is not without
limitations. Self-report measures of adherence run the risk of underreporting nonadherence
while serum drug assays of drugs with short half-lives provide limited understanding beyond
recent adherence patterns. A single, isolated serum drug assay was used as the component of
composite adherence score, rather than assessing variability over several trough blood level
results. In addition, clinician collateral reports used in this study were provided by two clinic
providers, both of whom had limited first-hand knowledge of the patient’s adherence behaviors
in the year prior to the clinic visit.
Statistical Analysis
For the purpose of this study, nonadherence was a dichotomized variable (all or nothing
phenomena). While necessary to reduce response bias associated with self-reported measures of
adherence, dichotomizing the phenomena can result in loss of dimensionality. Finally, analysis
of data using logistic regression requires caution when interpreting results as findings do not
indicate causality but rather demonstrate association and prediction (Polit & Beck, 2008).
Summary
This research study attempted to examine the impact of six predictor variablesdemographic, time posttransplant, immunosuppressant regimen, health beliefs, social support,
and symptom experience on IST adherence. This chapter presented a description of study
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procedures, a description of study participants, and explanations for the choice of statistical tests
used for hypothesis testing.
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CHAPTER FOUR: RESULTS
The purpose of this study was to examine demographic variables, time since transplant,
immunosuppressive agents, health beliefs, social support, and symptom experience and test their
relationship to adherence based upon the Health Decision Model (Eraker, Becker, Strecher, &
Kirscht, 1984).
The purpose was achieved through the testing of ten hypotheses. In these hypotheses,
demographic variables, time since transplant, IST agents, health beliefs, social support, and
symptom experience were considered independent variables while immunosuppressant
adherence was considered the dependent variable.
Data were collected over a fourteen month period. Combining both participant and
investigator completed instruments resulted in a total of 91 scale items and 18 demographic
items. Data were analyzed using SPSS 19.0 for Windows.
Description of the Sample
Of the 106 individuals approached, a total of 103 (97%) consented to participate. Of
these, 98 (95%) met final study inclusion criteria and were used in the data analyses. The sample
(N = 98) was represented by males (n = 57, 58%) and females (n = 41, 42%) ranging in age from
25 to 84 years (M = 57.2, SD = 12.75) with 43% (n = 42) of the sample < 55 years of age and
54.1% (n = 53) of the sample > 55 years of age. Time posttransplant ranged from 3 years to 14
years (M=4.9, SD = 1.72) with 67.3% (n =66) of the sample 3-< 5 years posttransplant, and
32.7% (n = 32) of the sample 6 years or more from transplant. The typical participant was a
57.19- year old nonhispanic, white married male, 4.95-years from transplant, not currently
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employed, receiving an annual income ranging between $10,000-$29,999 per year, having some
college education, and insured by Medicare. In addition, the typical participant’s IST regimen
included 2.44 medications and consisted of tacrolimus (Prograf) in combination with either
mycophenolate sodium (Myfortic) or mycophenolate mofetil (Cellcept) with or without
Prednisone. Additional demographic information for the sample is presented in Table 2.
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Table 2 Demographic Characteristics of the Sample
Variable
Age

n
98

Frequency %

Age
< 55 years of age
> 55 years of age

42
53

42.9
54.1

Gender
Male
Female

57
41

58.2
41.8

Time Posttransplant

98

Time Posttransplant
3-5 years
6 years or greater

66
32

Mean
57.19

SD
12.74

Range
25-84

4.95

1.71

3-14

67.3
32.7

Race
White
African American
Asian
American Indian / Alaska Native
Native Hawaiian / Pacific Islander

69
27
2
0
0

70.4
27.6
2
0
0

Ethnicity
Not Hispanic or Latino
Hispanic or Latino

80
18

81.6
18.4

Marital Status
Married / Living Together
Single
Separated / Divorced
Widowed

69
12
10
7

70.4
12.2
10.2
7.1

_____________________________________________________________________________
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Variable

n

Employment Status
Not Currently Employed
Full-time (36-40 hours per week)
Part-time (< 36 hours per week)

62
31
5

Highest Level of Education
Some College
High School or Equivalent
Bachelor’s Degree
Vocational / Technical School (2 year)
Master’s Degree

Frequency %

Mean

SD

Range

63.3
31.6
5.1

31
29
21
11
6

31.6
29.6
21.4
11.2
6.1

Annual Reported Income
<$10,000
$10,000-$29,999
$30,000-$59,999
$60,000-$99,999
$100,000-$249,999

12
32
26
17
10

12.2
32.7
26.5
17.3
10.2

Primary Insurance
Medicare
Private Insurance
Medicaid
Self-Pay

54
39
3
2

55.1
39.8
3.1
2

_____________________________________________________________________________
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Variable

n

Immunosuppressant Medication
tacrolimus (Prograf)
prednisone
mycophenolate sodium (Myfortic)
mycophenolate mofetil (CellCept)
sirolimus (Rapamune)
azathioprine (Imuran)
lefluonamide (Arava)

92
53
43
40
6
3
2

Number of IST Medications in Regimen

98

-

2.44

.593

1-4

Total IST Pills in Medication Regimen

98

-

4.73

1.36

2-8

Total Times Per Day Taking Meds

98

-

1.99

.176

1-3

IST Medication Complexity Index

98

-

24.31

11.56

4-72

Serum Creatinine

98

-

1.34

.509

0.62-4.29

Serum Drug Assay
tacrolimus (Prograf)
sirolimus (Rapamune)

94
5

-

6.93
11.26

2.73
4.56

1.50-18.30
6.2-18.7

Frequency %

Mean

SD

Range

93.9
54.1
43.9
40.8
6.1
3.1
2.0

_____________________________________________________________________________
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Adherence Demographics of Sample
A composite adherence score (CAS) (self-report nonadherence, one clinician response of
“fair” or lower adherence, and non-therapeutic serum drug assay) determined adherence
classification of study participants. Of the total sample population (N = 98), 39.8% (n = 39)
were classified as adherent, with 60.2% (n = 59) identified as nonadherent. Of the participants
identified as adherent (n = 39, 39.8%), 59% (n = 23) were males and 41% (n = 16) were females.
Adherent participants were typically less than 55 years of age (n = 23, 59%) and 5 years or less
from time of initial transplant (n = 27, 69.2%). Eighty-three percent (n = 81) of participants
were adherent to medication taking behaviors while 64.3% (n =63) were adherent to medication
timing behavior. Table 3 summarizes adherence demographics of the sample.
Table 3 Adherence Demographics of Sample
Nonadherent

Composite Adherence Score
(CAS ) Component
n
BAASIS

Frequency %

Adherent
n

Frequency %

41

41.8

57

58.2

Clinician Collateral

5

5.1

93

94.9

Serum Drug Assay

31

31.6

67

68.4

Composite Adherence Score

59

60.2

39

39.8
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Scores on Adherence Measures
Prior to hypotheses testing, descriptive statistics were obtained to describe and
summarize data for adherence measures. Continuous independent variable scores were
examined for measures of central tendency, outliers, and characteristics of distribution.
Measures of Central Tendency
Measures of central tendency for continuous independent variables were calculated.
Overall, study participants demonstrated strong beliefs regarding the necessity for taking
medications. The mean Necessity Concerns Differential score (m = 2.42) indicated study
participants rated the beliefs about the necessity for taking medications higher than the concerns
over taking medicines as further supported by the overall low mean BMQ Concerns subscale
score. Of the dimensions of social support, participants perceived greater overall emotional /
informational social support (m = 33.78). Participants also experienced a higher degree of
symptom frequency as compared to symptom distress. Table 4 summarizes measures of central
tendency for continuous independent variables used in this study.
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Table 4 Measures of Central Tendency for Independent Variables
Independent Variable

N

M

Age
Time posttransplant
IST Medication Complexity Index
Beliefs About Medicines (BMQ)
Necessity subscale
Concerns subscale
Necessity Concerns Differential

98
98
98

57.17
4.95
24.31

12.75
1.72
11.56

25-84
3-14
4-72

98
98
98

23.01
10.93
2.42

3.61
3.78
1.14

5-25
5-23
-1.60-4.0

MSSS
Tangible (TAN)
Positive Social Interaction (POS)
Emotional / Informational (EMI)
Affectionate (AFF)
MSSS Total

98
98
98
98
98
98

16.72
13.12
33.78
13.69
19.33

4.20
2.46
7.04
2.15
3.51

4-20
5-15
8-40
4-15
7-23

MTSOSD-59R Total Ridit Scores
Symptom Distress
Symptom Frequency

98
98
98

9.81
29.81

6.10
6.02

0-30.4
19.1-43.5

73

SD

Range

Outliers
Histograms and boxplots were visually inspected to identify outlying cases. Minimal
outliers were identified for time posttransplant (2), IST medication complexity index (1), and
MTSOSD-59R symptom distress total ridit scores (1) with no outliers noted to be severe,
extending 3 box lengths beyond the plot. All MSSS scales had identifiable outliers (TAN =6;
POS =3; EMI =7; AFF =4; MSSS total =7); however, no outliers extended beyond three box
lengths. Both BMQ subscales contained minimal outliers (BMQ Necessity =3; BMQ
Concerns =1) with both including extreme outliers extending beyond 3 box lengths from the plot
(BMQ Necessity =2; BMQ Concerns =1).
All outlying cases were considered to be both minimal in frequency and valid
components of the sample and were included in the analysis.
Tests of Normality of Distribution
Normality of distribution of all continuous independent variable values / scores (age, time
posttransplant, IST medication complexity index, BMQ subscales, MSSS subscales, MSSS total
scale, MTSOSD-59R symptom frequency total ridit, MTSOSD-59R symptom distress total ridit)
was calculated using measures of skewness, kurtosis, and calculated Kolmogorov-Smirnov (K-S)
value. Results showed values for age and scores for the BMQ Concerns, and MTSOSD-59R
Symptom Frequency total ridit scores were normally distributed within adherence classifications
as evidenced by both skewness and kurtosis values between -1 and 1 and further supported by
non-significant K-S values. Table 5 summarizes results.
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Table 5 Tests of Normality of Distribution
Variable
Age
Time posttransplant
IST Medication
Complexity Index
Beliefs About
Medicines (BMQ)
Necessity
Concerns
Necessity Concerns
Differential
MSSS
Tangible (TAN)
Positive Social
Interaction (POS)
Emotional /
Informational (EMI)
Affectionate (AFF)
MSSS Total
MTSOSD-59R Total
Ridit Scores
Symptom Frequency
Symptom Distress

Skewness
Nonadherent

Kurtosis

Adherent

Nonadherent

Kolmogorov-Smirnov (K-S)

Adherent

Nonadherent

Adherent

p
Nonadherent

Adherent

-.373
1.197

-.107
.360

-.423
6.520

-.542
-.890

.094
.145

.102
.136

.200
.003

.200
.068

1.086

3.291

.244

-.954

.188

.221

.000

.000

.311
.551

.378
.612

.613
-.029

.741
.489

.290
.114

.258
.140

.000
.053

.000
.051

-.968

-.761

.753

.709

.113

.144

.060

.041

-1.165

-2.009

.476

3.742

.187

.271

.000

.000

-1.160

-1.709

.734

2.417

.226

.332

.000

.000

-1.182
-2.216
-1.258

-1.603
-1.916
-1.660

1.172
5.412
1.527

1.706
4.110
2.092

.173
.306
.150

.238
.329
.234

.000
.000
.000

.000
.000
.000

.309
.466

.444
.981

-.955
-.459

-.268
1.800

.105
.103

.114
.140

.166
.193

.200
.051
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Estimation of Internal Consistency
Given that the target sample size was achieved, reliability of each of the variable scales
was estimated by means of Cronbach’s alpha (a). The BMQ necessity subscale achieved an
acceptable alpha value greater than .70: BMQ necessity subscale (n = 98, α =.92). The BMQ
concerns subscale (n = 98, α = .68) fell just short of an acceptable estimate. These alphas
compared favorably to those reported by earlier researchers: BMQ necessity subscale (α = .55)
and BMQ concerns subscale (α = .73) (Horne et al., 1999).
All subscales of the MSSS social support scale as well as the total MSSS scale score
achieved equally acceptable alpha values: four item TAN (n = 98, α = .93), eight item EMI (n =
98, α = .95), three item AFF (n = 98, α = .88), three item POS (n = 98, α = .93), and eighteen
item MSSS total score (n = 98, α = .96). Values compared favorably to previously published
values: TAN (n = 98, α = .84), EMI (n = 98, α = .80), AFF (n = 98, α = .86), POS (n = 98, α =
.87), and MSSS total score (n = 98, α = .88) (National Multiple Sclerosis Society, 1997). Table 6
summarizes internal consistency estimation values.
Consistent with previous research reporting psychometric properties of the MTSOSD59R scale, internal consistency was not appropriate or permitted and thus not estimated for the
purpose of this study.
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Table 6 Estimation of Internal Consistency as Reliability
Instrument
Beliefs About Medicines (BMQ)
Necessity
Concerns

N of items

Modified Social Support Scale (MSSS)
Tangible (TAN)
Emotional / Informational (EMI)
Affectionate (AFF)
Positive Social Interaction (POS)
MSSS Total Score

Chronbach’s alpha

5
5

.92
.68

4
8
3
3
18

.93
.95
.88
.93
.96

Hypothesis Testing
Ten hypotheses were posed based on the Health Decision Model as adapted for use in
this study (see Figure 1). Due to the dichotomous nature of the dependent variable, the
relationship between independent variables and composite adherence group classifications
(hypotheses 1, 3, 5, 7, and 9) were tested using Spearman’s correlation coefficient. The robust
independent samples t tests was used to test for differences in mean independent variable scores
among adherence classification groups and specified demographic groups (age, gender, time
posttransplant). Independent variables that demonstrated a significant relationship to adherence
group classification were entered into the final regression analysis.
Categorical Demographic Variables
A two-tailed Spearman’s rho correlation coefficient was calculated for the relationship
between the categorical demographic variables of age groups, gender, race, ethnicity, marital
status, employment status, education, insurance, income level, and time posttransplant groups.
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A low, negative correlation that was significant (r = -.213, p=.035) was found between age as
grouped into younger (< 54 yrs) and older (> 55 yrs) participants. Older (> 55 yrs) transplant
recipients were less adherent than younger (< 54 yrs) recipients. Table 7 summarizes correlation
statistics for all categorical demographic variables.
Table 7 Correlations Between Demographic Characteristics and Composite Adherence Groups
Demographic Variable
Age group (<54yrs; > 55yrs)
Gender
Race
Ethnicity
Marital status
Education
Insurance
Income
Time posttransplant groups (< 5 yrs; > 6 yrs)

n
98
98
98
98
98
98
98
98
98

r
-.213
-.013
-.111
.063
-.129
-.048
-.050
-.053
-.033

p (two-tailed)
.035
.896
.275
.540
.207
.638
.628
.605
.750

* p <.05
Hypothesis 1
Hypothesis 1: There will be a significant negative relationship between the predictor
variable of time posttransplant as measured in years and composite adherence group
classification.
A one –tailed Spearman’s rho correlation coefficient was calculated for the relationship
between the predictor variable of time posttransplant as measured in years and composite
adherence group classification. A weak, negative correlation was found (r = -.053, p=.303). The
research hypothesis was rejected. Time posttransplant was not related to composite adherence
group classification.
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Hypothesis 2
Hypothesis 2: There will be a significant relationship between the predictor variable of
age as measured in years and composite adherence group classification.
A two-tailed Spearman’s rho correlation coefficient was calculated for the relationship
between the predictor variable of age as measured in years and composite adherence group
classification. A weak, negative correlation that was found (r = -.159, p = .118). The hypothesis
was rejected. There was no significant relationship between the predictor variable of age as
measured in years and composite adherence group classification.
Hypothesis 3
Hypothesis 3: There will be a significant relationship between medication complexity
index scores and composite adherence group classification.
A two-tailed Spearman’s rho correlation coefficient was calculated for the relationship
between the predictor variable of medication complexity index scores and composite adherence
group classification. A weak, negative correlation that was found (r = -.038, p = .711). The
hypothesis was rejected. There was no significant relationship between medication IST
complexity index scores and composite adherence group classification.
Hypothesis 4
Hypothesis 4: There will be a significant difference in IST medication complexity scores
between composite adherence group classifications.
IST medication complexity index scores of nonadherent and adherent adult renal
transplant recipients were compared using an independent –samples t test. Levene’s test for
equality of variance (F = .218, p = .641) assured that the variances in scores were equally
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distributed. No significant difference was found (t (96) = .283, p=.778). Hypothesis 4 was
rejected. Nonadherent and adherent participants had similar IST complexity scores. Table 8
summarizes results.
Table 8 Group Differences for IST Medication Complexity Scores-Adherent / Nonadherent
Variable / Group

Minimum Maximum

M

SD

Nonadherent (n =59)

4

72

24.58

11.87

Adherent (n =39)

4

42

23.90

11.22

t (df)
.283(96)

P*
.778

*p < .05
Additional t-test analysis was conducted comparing the mean IST complexity index
scores between males and females, younger (< 54 yrs) and older (> 55 years) participants, and
time posttransplant groups as grouped around the mean (< 5 yrs posttransplant and 6 yrs or more
posttransplant). While no significant differences in complexity scores were found between
gender and age groups, the mean IST complexity score of participants 5 years or less
posttransplant was significantly lower (m = 22.24, sd = 12.095) than the means scores of
participants 6 or more years from transplant (m = 28.56, sd = 9.147). Table 9 summarizes group
differences for IST medication complexity index scores.
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Table 9 Group Differences for IST Medication Complexity Scores-Gender, Age Groups, Time
Posttransplant Groups
Variable / Group
Gender (N=98)
Male (n=57)
Female (n =41)
Age (N =98)
< 54 yrs (n=45)
> 55 yrs (n =53)
Time posttransplant (n = 98)
< 5 yrs (n = 66)
> 6 yrs (n = 32)

Minimum

Maximum

M

SD

t (df)

P*

4
4

48
72

22.56
26.73

10.84
12.22

-1.781 (96)

.078

4
4

72
48

24.76
23.92

12.45
10.86

.353 (96)

.725

4
12

72
48

22.24
28.56

12.10
28.56

-2.613 (96)

.010

*p < .05
Hypothesis 5
Hypothesis 5: There will be a significant relationship between the predictor variable of
health beliefs as measured by the BMQ Necessity and BMQ Concerns subscale score and
composite adherence group classification.
A Spearman’s rho correlation coefficient was calculated for the relationship between
BMQ Necessity and BMQ Concerns subscales of the Beliefs About Medicines Questionnaire
and composite adherence group classification. A low, positive correlation that was not
significant was found between the BMQ necessity subscale (r = .160, p = .116) and composite
adherence group classification. A low, negative correlation that was not significant was found
between the BMQ concerns subscale (r = -.124, p = .223) and composite adherence group
classification. Hypothesis 5 was rejected. Scores on both the BMQ Necessity and BMQ
Concerns subscales were not related to composite adherence group classification.
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Hypothesis 6
Hypothesis 6: There will be a significant difference in BMQ Necessity subscale scores,
BMQ Concern subscale scores, and BMQ Necessity/Concerns Differential scores between
composite adherence group classifications.
Independent-samples t tests were calculated comparing the mean BMQ Necessity, BMQ
Concerns, and BMQ Necessity/Concerns Differential scores between adherent and nonadherent
participants. Table 10 summarizes results with the reported p values reflective of the Levene’s
statistic. Hypothesis 6 was rejected as no significant differences were found in scores between
groups. The mean scores of nonadherent participants were not significantly different from the
mean scores of adherent participants across all BMQ scores.
Table 10 Group Differences for Nonadherent / Adherent Groups-Beliefs About Medicines
Variable / Group
BMQ Necessity (N = 98)
Nonadherent (n = 59)
Adherent (n = 39)
BMQ Concern (N =98)
Nonadherent (n = 59)
Adherent (n = 39)
Necessity / Concerns Differential
(N =98)
Nonadherent (n = 59)
Adherent (n = 39)

Minimum

Maximum

M

SD

t (df)

P*

5
16

25
25

22.58
23.67

4.32
2.02

-1.682 (88)

.096

5
5

23
20

11.25
10.44

3.99
3.43

1.049 (96)

.297

2.26
2.65

1.27
.88

-1.632 (96)

.106

-1.60
.00

4.00
4.00

*p < .05
Additional analyses were conducted comparing the mean BMQ scale scores between
males and females, younger (< 54 yrs) and older (> 55 years) participants, and time
posttransplant groups (< 5 yrs posttransplant and 6 yrs or more posttransplant). Reported p
values were based on Levene’s test for equality of variances. No significant differences in all
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scale scores between gender, age groups, and time posttransplant groups were found. Table 11
summarizes results.
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Table 11 Group Differences for Gender, Age Groups, Timeposttransplant Groups-Beliefs About Medicines
BMQ Necessity Scale (N=98)

Group
Gender (N=98)
Male (n=57)
Female (n =41)
Age (N =98)
< 54 yrs (n=45)
> 55 yrs (n =53)
Time posttransplant (n = 98)
< 5 yrs (n = 66)
> 6 yrs (n = 32)
Group
Gender (N=98)
Male (n=57)
Female (n =41)

Minimum

Maximum

M

SD

t(df)

P*

5
5

25
25

23.33
22.56

3.340
3.950

1.046 (96)

.298

5
5

25
25

23.38
22.70

3.632
3.53

.929 (96)

.355

13
5

25
25

23.41
22.19

2.683
4.961

1.304 (40)

.200

BMQ Concern Scale (N=98)
Minimum

Maximum

M

SD

t(df)

p

5
5

23
20

10.86
11.02

3.819
3.778

-.212 (96)

.833

Age (N =98)
< 54 yrs (n=45)
> 55 yrs (n =53)

5
5

23
20

10.67
11.15

4.023
3.592

-.629 (96)

.531

Time posttransplant (n = 98)
< 5 yrs (n = 66)
> 6 yrs (n = 32)

5
6

23
18

10.92
10.94

4.017
3.311

-.016 (96)

.987

*p < .05
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BMQ Necessity / Concerns Differential (N=98)

Group

M

SD

t(df)

P*

Minimum

Maximum

-1.600
-.800

4.00
4.00

2.49
2.31

1.09
1.22

.799 (96)

.426

Age (N =98)
< 54 yrs (n=45)
> 55 yrs (n =53)

-1.600
-.600

4.00
4.00

10.67
11.15

4.023
3.592

1.005 (96)

.318

Time posttransplant (n = 98)
< 5 yrs (n = 66)
> 6 yrs (n = 32)

-.800
-1.600

4.00
3.80

2.50
2.25

1.09
1.24

1.003 (96)

.318

Gender (N=98)
Male (n=57)
Female (n =41)

*p < .05
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Hypothesis 7
Hypothesis 7: There will be a significant positive relationship between the predictor
variable of social support as measured by MSSS total and subscale (TAN, POS, EMI, AFF)
scores and composite adherence group classification.
A one-tailed Spearman’s rho correlation coefficient was calculated for the relationship
between all MSSS subscale scores and total scale scores and composite adherence group
classification. Low, positive correlations that were significant were found between the Tangible
Support (TAN) subscale (r = .215, p =.017), Emotional Informational Support (EMI) subscale
(r = .274, p = .003), Positive Social Interaction (POS) subscale (r = .199, p = .025), MSSS total
scale scores (r = .274, p =.003) and composite adherence group classification. A low, positive
correlation that was not significant was found between the Affectionate Support (AFF) subscale
(r = .054, p = .297) and composite adherence group classification. The hypothesis was partially
accepted. Participants that were adherent perceived significantly greater tangible,
emotional/informational, positive social interaction, and overall social support than
nonadherent participants.
Hypothesis 8
Hypothesis 8: There will be a significant difference in MSSS subscale and total scale
scores between composite adherence group classifications.
Independent-samples t tests were calculated comparing all mean MSSS subscale (TAN,
POS, EMI, AFF) scores and total MSSS scale scores between adherent and nonadherent
participants. Reported p values reflect the Levene’s test for equality of variances. A significant
difference was found between the mean scores of the EMI subscale (t (96) = -2.491, p =.014),
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POS subscale (t (95) = -2.1.06, p =.038), and MSSS total scale scores (t (96) = -2.261, p =.026)
and composite adherence group classification. The mean scores of the nonadherent group for
emotional, positive social interaction, and total overall social support were significantly lower
than the mean scores of adherent participants. Hypothesis 8 was partially accepted. There was a
significant different between the mean scores of the EMI, POS, and MSSS total scale scores for
nonadherent and adherent participants. Table 12 summarizes results.
Table 12 Group Differences for Nonadherent / Adherent Groups-Modified Social Support
Scales
Variable / Group
TAN (N = 98)
Nonadherent (n = 59)
Adherent (n = 39)

Minimum

Maximum

M

SD

t (df)

P*

4
4

20
20

16.15
17.59

4.326
3.885

-1.675 (96)

.097

EMI (N =98)
Nonadherent (n = 59)
Adherent (n = 39)

8
20

40
40

32.37
35.90

7.488
5.757

-2.491(96)

.014

AFF (N = 98)
Nonadherent (n = 59)
Adherent (n = 39)

4
8

15
15

13.51
13.97

2.438
1.597

-1.143 (95.9)

.256

POS (N = 98)
Nonadherent (n = 59)
Adherent (n = 39)

5
8

15
15

12.73
13.72

2.671
1.973

-2.106 (94.7)

.038

MSSS total score (N = 98)
Nonadherent (n = 59)
Adherent (n = 39)

7
11

23
23

18.69
20.29

3.679
3.033

-2.261 (96)

.026

*p < .05
Additional analyses were conducted comparing the mean MSSS subscale scores (TAN,
POS, EMI, AFF) and MSSS total scale scores between males and females, younger (< 54 yrs)
and older (> 55 years) participants, and time posttransplant groups (< 5 yrs posttransplant and 6
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yrs or more posttransplant). Reported p values were based on Levene’s test for equality of
variances.
While no significant differences were found between the mean scores of age groups and
time posttransplant groups, a significant difference between the mean scores of men and women
on the TAN subscale (t (64) = 2.842, p = .006), AFF subscale (t (96) = 2.081, p = .040), and
MSSS total scale score (t (96) = 2.263, p = .026). The mean TAN, AFF, and MSSS total scale
scores for men were significantly higher than women. Table 13 summarizes test results.
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Table 13 Group Differences for Gender, Age Groups, Timeposttransplant Groups-Modified Social Support Scales
Tangible Support (TAN) (N=98)

Group
Gender (N=98)
Male (n=57)
Female (n =41)

Minimum

Maximum

M

SD

t(df)

P*

8
4

20
20

17.77
15.27

3.235
4.930

2.842 (64)

.006

Age (N =98)
< 54 yrs (n=45)
> 55 yrs (n =53)

4
4

20
20

16.07
17.28

4.750
3.613

-1.407 (81)

.163

Time posttransplant (n = 98)
< 5 yrs (n = 66)
> 6 yrs (n = 32)

6
4

16.85
16.47

3.986
4.656

.418 (96)

.677

Group
Gender (N=98)
Male (n=57)
Female (n =41)

20
20

Emotional Informational Support (EMI) (N=98)
Minimum

Maximum

M

SD

t(df)

p

20
8

40
40

34.65
32.56

5.972
8.219

1.457 (96)

.148

Age (N =98)
< 54 yrs (n=45)
> 55 yrs (n =53)

8
18

40
40

32.58
34.79

8.341
5.586

-1.516 (75)

.134

Time posttransplant (n = 98)
< 5 yrs (n = 66)
> 6 yrs (n = 32)

8
13

40
40

33.74
33.84

6.769
7.671

-.067 (96)

.947

*p < .05
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Affectionate Support (AFF) (N=98)

Group
Gender (N=98)
Male (n=57)
Female (n =41)
Age (N =98)
< 54 yrs (n=45)
> 55 yrs (n =53)
Time posttransplant (n = 98)
< 5 yrs (n = 66)
> 6 yrs (n = 32)
Group
Gender (N=98)
Male (n=57)
Female (n =41)

Minimum

Maximum

M

SD

t(df)

P*

8
4

15
15

14.07
13.17

1.657
2.616

2.081 (96)

.040

4
10

15
15

13.24
14.08

2.723
1.412

-1.847 (64)

.069

4
5

15
15

13.73
13.63

2.094
2.282

.220 (96)

.826

Positive Social Interaction (POS) (N=98)
Minimum

Maximum

M

SD

t(df)

p

7
5

15
15

13.49
12.61

2.180
2.737

1.773 (96)

.079

Age (N =98)
< 54 yrs (n=45)
> 55 yrs (n =53)

5
9

15
15

12.82
13.38

2.933
1.954

-1.082 (74)

.283

Time posttransplant (n = 98)
< 5 yrs (n = 66)
> 6 yrs (n = 32)

5
6

15
15

13.00
13.38

2.542
2.282

-.707 (96)

.481

*p < .05
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MSSS Total Scale Score (N=98)
Group
Gender (N=98)
Male (n=57)
Female (n =41)
Age (N =98)
< 54 yrs (n=45)
> 55 yrs (n =53)
Time posttransplant (n = 98)
< 5 yrs (n = 66)
> 6 yrs (n = 32)

M

SD

23
23

20.00
18.40

2.910
4.063

2.263 (96)

.026

7
12

23
23

18.68
19.88

4.223
2.686

-1.650 (72)

.103

7
9

23
23

19.33
19.33

3.408
3.769

.002 (96)

.999

Minimum
11
7

Maximum

*p > .05
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t(df)

P*

Hypothesis 9
Hypothesis 9: There will be a significant negative relationship between the predictor
variable of symptom experience as measured by MTSOSD-59R total ridit scores and composite
adherence group classification.
A one-tailed Spearman’s rho correlation coefficient was calculated for the relationship
between total ridit scores for MTSOSD-59R Symptom Occurrence and Symptom Distress scales
and composite adherence group classification. A low negative correlation that was not
significant was found (r = -.162, p = .055) for the relationship between Symptom Frequency
total ridit scores and composite adherence group classification. A low, negative correlation that
was also not significant was found (r = -.143, p =.081) between Symptom Distress total ridit
scores and composite adherence group classification. Hypothesis 9 was rejected. There was no
significant relationship between symptom experience and composite adherence group
classification. Table 14 identifies by rank order, the most prominent symptoms and associated
distress experienced by gender, age, time posttransplant, and adherence groups.
Additional analyses were conducted to determine the relationship between individual
symptoms and composite adherence group classification. Three symptoms demonstrated a
significant relationship with composite adherence group classification. Dizziness (r = .288, p
=.037), difficulty concentrating and / or memory problems (r = -.327, p =.016), and chest pain
(r = -.471, p =.036) demonstrated significant relationships with adherence group classification.
Adherent participants experienced significantly less chest pain, dizziness, and difficulty
concentrating or memory problems.
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Table 14 Symptom Distress-Gender, Age, Time Posttransplant, Adherence
Gender (N = 98)

Symptoms*
Tiredness
Wind
Lack of Energy
Bruise Easy
Joint Pain
Restlessness / Nervousness
Concentration / Memory Problems
Dizziness
Sleep Difficulties
Muscle Weakness

Prevalence
n (%)
65 (66.3)
61 (62.2)
59 (60.2)
57 (58.2)
56 (57.1)
56 (57.1)
54 (55.1)
53 (54.1)
52 (53.1)
47 (48.0)

Not Distressing
n
13
17
11
9
11
3
13
3
5
4

Males

%
41.9
51.5
32.4
33.3
34.4
9.7
40.6
10.7
16.7
16.0

Females
n
%
12
35.3
9
32.1
5
20
5
16.7
9
37.5
4
16.0
9
40.9
3
12
10
45.5
5
22.7

Distressing
n
18
16
23
18
21
28
19
25
25
21

Note: Rank order of the first 10 most prominent symptoms and associated distress by gender.
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Males

%
58.1
48.5
67.6
66.7
65.6
90.3
59.4
89.3
83.3
84

Females
n
%
22
64.7
19
67.9
20
80
25
83.3
15
62.5
21
84
13
59.1
22
88
12
54.5
17
77.3

Age (N = 98)

Symptoms*
Tiredness
Wind
Lack of Energy
Bruise Easy
Joint Pain
Restlessness / Nervousness
Concentration / Memory Problems
Dizziness
Sleep Difficulties
Muscle Weakness

Prevalence
n (%)
65 (66.3)
61 (62.2)
59 (60.2)
57 (58.2)
56 (57.1)
56 (57.1)
54 (55.1)
53 (54.1)
52 (53.1)
47 (48.0)

Not Distressing
< 54 yrs
n
%
12
42.9
10
40
5
19.2
7
5.6
9
39.1
1
4.3
12
60
2
9.5
5
21.7
6
28.6

> 55 yrs
n
%
13
35.1
16
44.4
11
33.3
7
8.4
11
33.3
6
18.2
10
29.4
4
12.5
10
34.5
3
11.5

Note: Rank order of the first 10 most prominent symptoms and associated distress by age.
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Distressing
< 54 yrs
n
%
16
57.1
15
60
21
80.8
16
69.6
14
60.9
22
95.7
8
40
19
90.5
18
78.3
15
71.4

> 55 yrs
n
%
24
64.9
20
55.6
22
66.7
27
47.4
22
66.7
27
81.8
24
70.6
28
87.5
19
65.5
23
88.5

Time Posttransplant (N = 98)

Symptoms*

Tiredness
Wind
Lack of Energy
Bruise Easy
Joint Pain
Restlessness / Nervousness
Concentration / Memory Problems
Dizziness
Sleep Difficulties
Muscle Weakness

Prevalence
n (%)

65 (66.3)
61 (62.2)
59 (60.2)
57 (58.2)
56 (57.1)
56 (57.1)
54 (55.1)
53 (54.1)
52 (53.1)
47 (48.0)

Not Distressing
< 5 yrs
posttransplant
n
%
16
38.1
17
45.9
12
28.6
8
22.2
16
42.1
3
8.1
13
38.2
5
14.3
11
32.4
9
29

> 6 yrs
posttransplant
n
%
9
39.1
9
37.5
4
23.5
6
28.6
4
22.2
4
21.1
9
45
1
5.6
4
22.2
0
0

Distressing
< 5 yrs
posttransplant
n
%
26
61.9
20
54.1
30
71.4
28
77.8
22
57.9
34
91.9
21
61.8
30
85.7
23
67.6
22
71

Note: Rank order of the first 10 most prominent symptoms and associated distress by time posttransplant.
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> 6 yrs
posttransplant
n
%
14
60.9
15
62.5
13
76.5
15
71.4
14
77.8
15
78.9
11
55
17
94.4
14
77.8
16
100

Adherence (N = 98)

Symptoms*
Tiredness
Wind
Lack of Energy
Bruise Easy
Joint Pain
Restlessness / Nervousness
Concentration / Memory Problems
Dizziness
Sleep Difficulties
Muscle Weakness

Prevalence
n (%)
65 (66.3)
61 (62.2)
59 (60.2)
57 (58.2)
56 (57.1)
56 (57.1)
54 (55.1)
53 (54.1)
52 (53.1)
47 (48.0)

Not Distressing
Nonadherent
n
%
14
32.6
16
42.1
10
27.8
11
28.2
16
40
4
10.8
12
30.8
1
3.3
10
27
7
21.9

Adherent
n
%
11
50
10
43.5
6
26.1
3
16.7
4
25
3
15.8
10
66.7
5
21.7
5
33.3
2
13.3

Distressing
Nonadherent
n
%
29
67.4
22
57.9
26
72.2
28
71.8
24
60
33
89.2
27
69.2
29
96.7
27
73
25
78.1

Note: Rank order of the first 10 most prominent symptoms and associated distress by adherence.
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Adherent
n
%
11
50
13
56.5
17
73.9
15
83.3
12
75
16
84.2
5
33.3
18
78.3
10
66.7
13
86.7

Hypothesis 10
Hypothesis 10: There will be a significant difference in MTSOSD-59R total ridit scores
between composite adherence group classifications.
An independent-samples t test was calculated comparing the mean MTSOSD-59R
Symptom Frequency and Symptom Distress total ridit scores of nonadherent and adherent longterm adult renal transplant recipients. No significant difference was found between groups for
both Symptom Frequency total ridit scores (t (96) = 1.704, p = .092) and Symptom Distress total
ridit scores (t (96) = 1.232, p = .221). The mean scores of adherent participants were not
significantly different from nonadherent participants for both the MTSOSD-59 R Symptom
Frequency and Symptom Distress total ridit scores. Table 15 summarizes group scores.
Table 15 Group Differences Nonadherent / Adherent-MTSOSD-59R Symptom Occurrence and
Symptom Distress Total Ridit Scores
Variable / Group
MTSOSD-59R Symptom Frequency
Nonadherent (n = 59)
Adherent (n = 39)
MTSOSD-59R Symptom Distress
Nonadherent (n = 59)
Adherent (n = 39)

Minimum

Maximum

M

SD

t (df)

P*

20.57
19.10

41.62
43.46

30.64
28.54

5.82
6.17

1.704 (96)

.092

1.77
.000

24.46
32.42

10.42
8.88

5.90
6.35

1.232 (96)

.221

*p < .05
Additional analyses were conducted comparing the means of Symptom Frequency and
Symptom Distress total ridit scores between males and females, younger (< 54 yrs) and older (>
55 years) participants, and time posttransplant groups (< 5 yrs posttransplant and 6 yrs or more
posttransplant). The reported p value reflected the Levene’s statistic. No significant difference
in mean scores was found between groups. Table 16 summarizes results.
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Table 16 Group Differences Gender, Age Groups, Time Posttransplant Groups-MTSOSD59R Symptom Occurrence and Symptom Distress Total Ridit Scores
MTSOSD-59R Symptom Frequency (N=98)

Group

Maximum

M

SD

19.11
20.57

42.09
43.46

28.96
30.98

6.01
5.91

-1.647 (96)

.103

Age (N =98)
< 54 yrs (n=45)
> 55 yrs (n =53)

19.11
20.57

42.09
43.46

30.03
29.61

6.39
5.74

.345 (96)

.731

Time posttransplant (n = 98)
< 5 yrs (n = 66)
> 6 yrs (n = 32)

19.10
20.24

29.66
30.11

6.21
5.68

-.349 (96)

.728

Gender (N=98)
Male (n=57)
Female (n =41)

Group

Minimum

42.09
43.46

t(df)

P*

MTSOSD-59R Symptom Distress (N=98)
Minimum

Maximum

M

SD

.000
1.56

30.42
24.46

9.37
10.41

6.13
6.07

-.831 (96)

.408

Age (N =98)
< 54 yrs (n=45)
> 55 yrs (n =53)

.000
1.56

30.42
24.22

9.83
9.78

6.96
5.32

.037 (81)

.970

Time posttransplant (n = 98)
< 5 yrs (n = 66)
> 6 yrs (n = 32)

.000
1.77

30.42
17.65

10.18
9.04

6.61
4.86

.862

.391

Gender (N=98)
Male (n=57)
Female (n =41)

*p < .05
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t(df)

p

Logistic Regression Analysis
To answer the primary research question of which of six predictor variables
demographic variables, time since transplant, immunosuppressive agents, health beliefs, social
support, and symptom experience are most influential in predicting IST adherence in long-term
adult renal transplant recipients, a forward logistic regression was conducted. Predictor
variables demonstrating a significant relationship to adherence (age groups, TAN subscale, POS
subscale, EMI subscale, and MSSS total scale scores) were entered into the final logistic
regression analysis.
Prior to analysis, data were explored for missing values and outliers. Preliminary
multiple linear regression analysis was conducted to calculate Mahalanobis distance and to
evaluate multicollinearity. Initial results indicated multicollinearlity was violated as tolerance
statistics were less than .1 for all social support scales. To address this problem, the independent
variable of MSSS total scale score was removed. The resultant table of regression coefficients
(see Table 18) indicated multicollinearity was not violated since tolerance statistics for all three
independent variables were greater than 0.1. Data were explored to determine which cases
exceeded the Mahalanobis distance critical value of x2 (3) = 16.266 at p = .001. One subject
exceeded this value (case #86) and was eliminated from analysis.
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Table 17 Collinearity Statistics
Collinearity Statistics

Variable
(TAN)Tangible Support Subscale
(EMI) Emotional Informational Support Subscale
(POS) Positive Social Interaction Subscale

Tolerance

VIF

.587

1.705

.297

3.366

.366

2.732

Binary logistic regression using the Forward: LR method was then conducted to
determine which independent variables (age [< 54 yrs, > 55 yrs], TAN subscale, EMI subscale,
POS subscale) were predictors of adherence group classification (adherent/nonadherent).
Regression results indicated the overall model of two predictors (age [< 54 yrs, > 55 yrs] and
EMI subscale) was statistically reliable in distinguishing between adherent and nonadherent
participants (-2 Log Likelihood 116.244; Goodness-of-Fit x2 (2) = 13.664, p = .001). The model
correctly classified 69.1% of the cases. Regression coefficients are presented in Table 18. Wald
statistics indicated that age (< 54 yrs, > 55 yrs) and EMI subscale significantly predicted
adherence group classification. Odds ratios for the EMI (eB = 1.105) variable indicated that as
the variable EMI increases by 1, participants were 1.105 times more likely to be classified as
adherent. Odds ratio for the variable age grouped (eB = 3.320) indicated that as age grouped
increased by 1, participants were 3.320 times as likely to be classified as adherent.
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Table 18 Regression Coefficients
B

EMI (Emotional / Informational )
subscale
Age group (< 54 yrs; > 55 years)
Constant

Wald

df

p

Odds Ratio

95% Confidence
Interval
Lower
Upper

.100

7.028

1

.008

1.105

1.026

1.189

1.200
-4.435

6.871
10.142

1
1

.009
.001

3.320

1.354

8.144

Summary
The results of this study demonstrated weak, but significant relationships between age
group, TAN subscale, POS subscale, EMI subscale, and MSSS total scale scores and adherence
group classification. While perceived emotional and information social support and being older
significantly predicted adherence, odds ratios demonstrated moderate change in the likelihood of
adherence on the basis of a one unit change in age or perceived emotional/informational support.
Thus, age and perceived emotional/informational support distinguished moderately between
nonadherent and adherent long-term adult renal transplant recipients.
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CHAPTER FIVE: DISCUSSION
During the past ten years, many studies have explored predictors of immunosuppressant
(IST) medication adherence in adult renal transplant recipients. To date, this is the first study to
examine predictors of IST medication adherence in a population of long-term renal transplant
recipients. The purpose of this study was to examine demographics, time posttransplant,
immunosuppressive agents, health beliefs, social support, and symptom experience and test their
relationship to IST adherence based upon the Health Decision Model as adapted by the principal
investigator for use in this study. This chapter compares and contrasts study findings with results
reported in previous research. Implications for nursing practice as well as recommendations for
future research are discussed.
Sample

While the sample in this study was similar to the U.S. renal transplant population as
reported by the Organ Procurement Transplant Network (2009), study findings should not be
generalized to the entire population. This study sample was similar to the U.S. renal transplant
population in terms of gender (58.2% men versus 60.4% nationally). Age group distributions
indicated a slightly older population in this study (see Table 19). Finally, while African
Americans were appropriately represented (27.6% versus 25.7% nationally), Asian and “other”
race categories were underrepresented.
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Table 19 Comparison of Study Participants and U.S. Transplant Population
Characteristic
Age
18-34
35-49
50-64
65+
Gender
Male
Female
Race
White
Black
Asian
Other / unknown
Ethnicity
Hispanic

Study (%)

U.S. Transplant Population (%)

6.1%
17.3%
46.9%
29.6%

13.8%
28.4%
41.1%
16.7%

58.2%
41.8%

60.4%
39.6%

70.4%
27.6%
2%
0%

53.4%
25.7%
5.5%
1.3%

18.2%

14.2%

Adherence
Though healthcare providers in this study setting considered long-term recipients
generally adherent, 60.2% of this study’s participants were nonadherent to their
immunosuppressant medications when defined as older (> 55 yrs) in this study. Variations in
methods of measuring IST adherence have contributed to the wide range of previously reported
adherence rates. When measured by self-report methods, IST adherence is often overestimated
(Osterberg & Blaschke, 2005). In contrast, a study by Russell et al. (2010) noted that use of a
self-report measure of adherence that captures timing adherence behaviors may contribute to an
overall low percentage of adherent participants in a sample where 86% of older renal transplant
recipients were identified as being nonadherent. Results from this study yielded similar findings.
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One study to date has used a composite score of adherence, similar to the one used for
this study. The composite score, used by Schmidt-Mohler et al. was composed of clinician
collateral reports and the same self-report measure used in this study (BAASIS) which captures
timing adherence (Schmid-Mohler, Thut, Wüthrich, Denhaerynck, & De Geest, 2010). Authors
of this study categorized participants as adherent, partially adherent, or nonadherent. However,
if findings were dichotomized, 76% of the sample would have been classified as nonadherent
(partially adherent or nonadherent). Results from this study yielded a similarly high rate of
nonadherence.
Age
The majority of studies have reported younger age as being associated with nonadherence
(Chisholm-Burns, Kwong, Mulloy, & Spivey, 2008; M. A. Chisholm, Lance, & Mulloy, 2005;
Denhaerynck et al., 2007; Frazier, Davis-Ali, & Dahl, 1994; Ghods, Nasrollahzadeh, & Argani,
2003; Greenstein & Siegal, 1998; Gremigni et al., 2007). Of these studies, few have clearly
defined younger and older age categories. In this study, age was assessed both as a continuous
variable and older/younger categorical variable. While findings from this study failed to
correlate age (continuous variable) with adherence, a significant, low negative correlation was
found when grouping participants into older and younger age groups. Older transplant recipients
(> 55 yrs) were identified as being less adherent than younger participants (< 54 yrs). Recent
studies defining “older” age groups yielded similar results with Chisholm-Burns et al. (2008)
reporting adherence as being lower among recipients 60 or more years of age and Russell et al.
(2011) reporting significant nonadherence (86%) in recipients 55 years of age or older.
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Time Posttransplant
The mean time posttransplant for participants in this study was 4.95 yrs. Analysis failed
to support a significant relationship between time posttransplant and adherence. Findings from
this study contrast with the majority of studies that reported increased time from transplant as
being significantly associated with nonadherence (Chisholm-Burns, et al., 2008; Chisholm, et al.,
2005; Chisholm, Mulloy, & DiPiro, 2005; Greenstein & Siegal, 1998; Ichimaru et al., 2008).
While earlier research findings support an inverse relationship between time posttransplant and
adherence to IST medications, one study to date has defined time posttransplant quartiles in an
effort to isolate the most useful time posttransplant to reinforce adherence. Chisholm-Burns et
al. (2008) concluded that recipients who were 4 years or less from transplant had higher overall
adherence to immunosuppressive medications than those 5 or more years from transplant
identifying a useful point for targeted interventions by healthcare providers. Both the frequency
of medication adjustments and follow-up appointments that occur during the first two years
following transplant could explain these findings. Given the lack of association between time
posttransplant (m=4.95 yrs) and adherence in this study, the quality of long-term primary care
provided by both the local primary care providers and the transplant clinic could be a possible
factor influencing long-adherence. Additionally, limited research has explored the effect of
comorbidities and their associated treatments (e.g. more medications) on IST adherence. The
burden of treating concomitant chronic conditions that increase with age may also be a factor.
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IST Medications
A calculated medication complexity index score (number of medications x number of IST
pills taken per day x number of times per day taking IST medications) was used to determine the
relationship between IST medications and adherence. Although no study to date conducted
within the adult renal transplant population has used this method of measure, all components of
the measure have been used either alone or in combination in many previous studies. Using this
method of measure, nonadherent participants were found to have a higher mean IST complexity
index score (m=24.58) than adherent participants (m=23.90), but the difference was not
statistically significant. In addition, study findings failed to find a significant relationship with
adherence. Results from previous studies are mixed (Goldfarb-Rumyantzev et al., 2011;
Schmid-Mohler, et al., 2010; Sketris et al., Vasquez, Tanzi, Benedetti, & Pollak, 2003; Weng et
al., 2005) with several factors providing possible explanations. While this study included only
IST medications in the analysis, other studies included either all prescribed medications or did
not clearly indicate which medications were used in the final analysis. In addition, the types of
medications, dosing frequencies, and medication regimens (combination or triple therapy) used
in previously reported studies reflected those represented in this study. However, the method or
combination of methods used to measure the dependent variable of adherence varied across all
studies. Finally, included in many study samples were participants in the immediate
posttransplant period (first 6 months) up to as few as 1-2 years posttransplant; the times during
which doses are frequently adjusted and/or medications weaned off and discontinued
(Prednisone) both of which can influence dosing complexity.
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Beliefs About Medicines
Findings from this study failed to support a significant relationship between beliefs about
medicines and adherence. These results are in contrast to those reported by Butler et al. (2004)
who concluded a lower belief in the need for medications was associated with nonadherence.
While results from this study indicated nonadherent participants has lower beliefs in the need for
medicines as reported by the mean Necessity scale score (m= 22.58 nonadherent versus m=23.67
adherent), the results failed to achieve statistical significance. One possible explanation for this
failure was the presence of a nonnormal distribution as influenced by Necessity scale score
outliers.
Additional study findings not achieving statistical significance in this study, may be of
clinical significance to healthcare providers. As compared to younger (< 54 yrs) participants,
older participants (> 55 yrs) had lower beliefs in the need for medicines and greater concerns
over the consequences of taking medicines. In addition, females demonstrated lower beliefs in
the need for medicines yet greater concern over the consequences of taking medicines. While
concerns over the consequences of taking medicines were virtually the same in both time
posttransplant groups (< 5 yrs, > 6 yrs), participants six or more years from transplant reported
lower beliefs in the need for medicines, which ultimately could influence adherence.
Social Support
Limited studies have explored social support within the context of IST adherence in the
adult renal transplant population. Of those that have, results have been mixed. Using the Social
Support Appraisal Index, a 23 item scale that measures the degree to which a person feels cared
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for, respected, and involved with family and friends, Russell et al. (2010) reported no significant
relationship between social support and IST adherence in a population of older (> 55 years)
recipients.
Using the shorter 5 item version of the Modified Social Support Scale (MSSS),
Chisholm-Burns et al. (2010) reported a significant relationship between social support and IST
adherence with affectionate support and an instrumental support item (help with household
functions) as being associated with total adherence summary scores. Of note in the ChisholmBurns et al. (2010) study was the reported mean age (m =48.9) of the sample.
Findings reported in this study, using the 18 item MSSS scale, mirrored findings reported
by Chisholm-Burns et. al. (2010) noting a significant relationship between social support and
increased adherence. However, contrary to findings reported by Chisholm-Burns et. al. (2010),
results from this study did not support a significant relationship between affectionate support
subscale items and adherence. One possible explanation for this finding could be the higher
overall percent of participants in this study that reported being married or living together (70.4%)
versus the lower percent of married participants in the Chisholm-Burns et. al. (2010) study
(28.7%).
Symptom Experience
Results obtained in this study failed to demonstrate a significant relationship between
symptom experience and adherence as measured by total overall symptom frequency and
symptom distress total ridit scores. In addition, results comparing differences in age, gender,
time posttransplant, and adherence groups failed to achieve significant levels despite the overall
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normal distribution of both symptom frequency and symptom distress total ridit scores. While
reported findings were not statistically significant, results comparing differences in groups may
be of clinical significance to healthcare providers.
It is important to note that no study to date has explored the relationship between
symptom experience and adherence using the updated MTSOSD-59R instrument reflective of
current IST regimens. In addition, of the studies exploring the effect of symptom experience on
adherence, all have been conducted within European or Canadian populations (Butler et al.,
2004; Denhaerynck et al., 2007; Sketris et al., 1994; Teixeira De Barros & Cabrita, 1999). This
study is the first to obtain data from a U.S. sample.
Findings reported in this study noted higher mean overall symptom frequency
[nonadherent (m = 30.64), adherent (m = 28.54)] and symptom distress ridit scores [ nonadherent
(m =10.42), adherent (m = 8.88)] in nonadherent participants, though results were not significant.
A study conducted by Teixeira De Barros and Cabrita (1999) in a population of Portuguese renal
transplant recipients using the MTSOSD 45 item scale reported similar results with significantly
higher overall symptom frequency and symptom distress ridit scores in nonadherent participants.
Perhaps the failure to achieve statistical significance in this study is due to possible cultural
variations in the measured level of symptom experience.
Age related findings reported in this study were in contrast to those reported by Teixeira
De Barros et al. (1999) who identified significantly higher mean symptom frequency scores in
older participants (> 40 yrs). Findings reported in this study noted younger participants (< 54
yrs) as having higher, though nonsignificant, overall mean symptom frequency scores. Mean
symptom distress scores were essentially the same in this study between age groups mirroring
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similar findings in the study by Teixeira De Barros et al. (1999). Cultural variations, variations
in IST regimens, instruments versions used to measure symptom experience, and variations in
defined age groups are all factors possibly influencing conflicting results.
Finally, no study to date has explored differences in symptom experience between groups
based on time posttransplant. Results in this study noted participants who were six or more years
from transplant had lower, though nonsignificant, mean symptom distress scores and higher
mean symptom frequency scores than participants who were 5 years or less from transplant.
Perhaps the higher mean symptom frequency scores found in those participants 6 or more years
from transplant is due to the development of symptoms similar to those associated with IST
therapy but also associated with comorbid conditions that can develop as a result of long-term
IST therapy (diabetes, hypertension). Conversely, perhaps the lower mean symptom distress
scores found in the same time posttransplant group (> 6 yrs time posttransplant) can be attributed
to tolerance or lessening of the intensity of symptom distress over time. Research in this area is
nonexistent. Further research within the context of current immunosuppressive regimens is
warranted.
Implications
Findings reported in this study add to the body of knowledge concerning IST adherence
in adult renal transplant recipients by focusing on a population defined as long-term. While
results from this study have implications for nursing education, practice, and policy, the greatest
implications lie within nursing practice.
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Nursing Practice
Of the 96,918 patients currently awaiting renal transplantation in the United States,
41,678 (43%) of those awaiting transplant are between 50 and 64 years of age (OPTN, 2012).
Results of this study demonstrate a negative correlation between age groups and adherence with
older (> 55 yrs) participants being less adherent than younger participants. Given the higher
percentage of nonadherent participants in this study (60%) and the mean age of participants in
this study (57.19 yrs), multidisciplinary teams providing care for long-term transplant recipients
may want to consider the findings in this study and implement both adherence screening
measures as well as interventions directed at modifiable variables associated with adherence in
this age group.
Nurses and advanced nurse practitioners working in outpatient clinic settings, may
consider screening patients in this age group annually for nonadherence by using a feasible
measure of self-report such as the BAASIS. Nurses could educate patients screened as
nonadherent about the use of reminder methods to enhance adherence (e.g. pillboxes, storing
medications with other items associated with daily rituals, keeping medications in the same
location). In addition, if medication complexity involving IST medications as well as
medications for other comorbid conditions is high, nurse practitioners collaborating with
nephrologists could review regimens in an effort to simplify medication dosing regimens to
promote better adherence.
Emotional/information social support, consisting of physical comforting, listening, and
empathizing along with the giving of advice and sharing information, was statistically reliable in
distinguishing between adherers and nonadherers. Considering the potential for change in social
111

support networks over the lifespan, licensed social workers as members of a multidisciplinary
team could be involved in both screening for changes in social networks in this age group as well
as integral in facilitating appropriate interventions.
For nonadherent patients demonstrating a lack of perceived emotional/informational
social support systems, a few interventions may be considered. The use of support groups is
common during the pretransplant phase of care to aid patients in determining if transplantation as
a therapy is an appropriate choice. Continuing these same support group sessions during the
posttransplant phase of care may provide recipients who are experiencing changes in social
support networks with a group of individuals able to provide relevant advice and information
during times of need.
Policy
The major focus of public policy addressing IST medication adherence in adult renal
transplant recipients is on extending lifetime Medicare coverage for costs related to IST therapy
to those patients receiving Medicare benefits for reasons other than disability. The results of this
study do not contribute to those policy initiatives.
While not public policy, findings from this study could be used to influence national
standards of care for kidney transplant recipients. Current Kidney Disease: Improving Global
Outcomes (KDIGO) practice guidelines for the care of kidney transplant recipients calls for
preventing, detecting, and treating nonadherence (Kasiske, Zeier, Chapman, Craig, Ekberg et al.,
2009). Given the relationship between social support and adherence, providing a measure for
ongoing screening for changes in social support systems as part of assessing for risk of

112

nonadherence may be of value in primary care settings. Findings also support the need for more
research funds to support the study of adherence in recipients in the United States.
Nursing Education
Results reported in this study may encourage both entry level and advanced practice
nursing education programs to incorporate content addressing the impact social support has on
adherence in long-term renal transplant recipients. More importantly, as part of ongoing support
and care provided over the lifespan of the transplant recipient, both the patient and family should
be periodically assessed for changes in social support structure as well as educated on the
importance of sustained social support and its relationship to adherence. Nurses also need
information on IST medications to better assist in patient teaching and follow-up care.
Necessary IST medication information such as drug-to-drug interactions, food-drug interactions,
side-effects, timing medications to sustain therapeutic blood levels, and therapeutic drug
monitoring should be a part of pharmacology content. Finally, advanced practice registered
nurses should stay alert to emerging research addressing once daily dosing regimens that may be
of benefit to patients struggling with adherence or those with highly complex medication
regimens.
Study Limitations
While an appropriate theoretical basis, reliable scale instruments, data collection
methods, and an adequate sample size added strength to the study, several limitations of this
study were evident and are discussed separately.
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Limitations related to the sample include the use of a convenience sample and associated
cross sectional design. Given the demographic differences between the sample population and
the U.S. transplant population (see Table 19), results may not be generalizable. Use of a cross
sectional design limits the assessment of adherence to one point in time. Given the opinion that
all patients are believed to be nonadherent to medication therapy at some point in time, use of
this design may fail to adequately represent overall adherence rates. However, given the high
percentage of nonadherent participants in this study (60.2%), this is most likely a minimal
limitation.
The self-report measure of adherence used in this study represents all dimensions of
medication taking behavior including timing. Of the participants in this study, 35.7% were
nonadherent with taking medications within 2 hours of the prescribed time. By classifying
participants with timing nonadherence as partially adherent, another dimension is represented
that may be amenable to intervention. Dichotomizing adherence results in loss of the
dimensionality of the concept.
Limitations are also associated with the components making up the composite score of
adherence (CAS) used in measure IST adherence in this study. The self-report measure of
adherence (BAASIS) used as a component of this study’s CAS, runs the risk of under-reporting
nonadherence as participants may have felt compelled to answer in a manner viewed as positive
by the investigator. Given the high rate of self-reported nonadherence (41.8%) as measured by
this instrument, this is also most likely a minimal limitation.
Another component of the CAS, clinician collateral reports, were provided by two
transplant clinicians with little knowledge of the medication taking behaviors of participants
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beyond the date of their annual clinic appointment. In addition, when asked face-to-face by
clinicians if they are having difficulty taking or getting IST medications (the standard clinic
adherence assessment in this study setting) participants may be fearful of answering truthfully.
However, given the observed interactions between clinical professionals and study participants
as well as other clinic patients, this factor is also felt to be of minimal limitation to this study.
The final component of the CAS score used in this study was the serum drug assay. In a
study assessing the diagnostic accuracy of measurement methods assessing adherence in renal
transplant patients, the CAS score identified as demonstrating 72.1% specificity in detecting
nonadherence assessed serum drug assay variability over several serum drug assay values
(Schäfer-Keller, Steiger, Bock, Denhaerynck, & De Geest, 2008). The use of a single serum
drug assay value versus assessing variability over several trough results may have resulted in the
inappropriate classification of participants with isolated nontherapeutic values as nonadherent.
This factor is believed by the author to be a major limitation of this study.
Recommendations for Future Research
Serving as the basis for all future research recommendations is the need for investigators
to continue to explore factors identified as influencing IST adherence within the context of more
consistently defined age and time posttransplant groups. As the adult renal transplant population
lives longer and continues to age, the influence of modifiable factors impacting adherence may
change over the lifespan of the recipient. By intentionally and consistently defining age groups
and time posttransplant intervals, relevant interventions may be more intently targeted during
long-term primary care of the adult renal transplant recipient.
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Given the conflicting research findings regarding the influence of IST medications
(dosing complexity) on adherence, further research is warranted. Future research should not
only explore medication complexity associated with IST medications, but also adherence related
to other prescribed medications necessary to sustain the health of transplanted grafts (antivirals,
antihypertensives, hypoglycemic agents, antibiotics). As both time from transplant and the risk
for the development of comorbidties associated with long-term IST therapy increases adherence
to such agents becomes just as critical. The potential addition of these additional prescribed
medications adds to the complexity of IST regimens which may increase the risk for
nonadherence.
While research regarding the influence of symptom experience on adherence in European
transplant recipients is available, lacking are studies conducted within a representative sample of
the U.S. transplant population. In addition, further analysis of these studies could help formulate
symptom profiles specific to IST regimens, gender groups, and ethnic groups.
Finally, given the lack of significant findings related to modifiable variables known to
influence adherence (health beliefs), research exploring the influence of the healthcare system
(transplant clinic, primary care setting) on adherence.
Summary and Conclusion
The purpose of this study was to examine demographics variables, time posttransplant,
immunosuppressive agents, health beliefs, social support, and symptom experience and test their
relationship to adherence. Using a cross sectional design, a convenience sample of 98 long- term
adult renal transplant recipients provided data for this study.
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The results of this study added to the current body of knowledge in the area of IST
adherence in adult renal transplant recipients. Findings from this study can be used to aid
healthcare personnel involved in the long-term care of adult renal transplant recipients in
identifying patients at risk for nonadherence. In addition, given the modifiable nature of social
support, found to be significantly associated with adherence in this study, healthcare personnel
can implement interventions appropriate to support participants experiencing lower perceived
social support.
Future research should continue to explore variables known to influence adherence
within the context of consistently defined age and time posttransplant groups. By consistently
defining groups, cut points could be delineated identifying more focused age groups and time
posttransplant intervals amenable to interventions designed to enhance adherence and improve
long-term outcomes.
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Invitation to Participate in Research

Predictors of Immunosuppressant Adherence
in Long Term Renal Transplant Recipients
Desired Participants: Kidney transplant recipients, age 18 at the time
of transplant.
Research Purpose: To learn about taking anti-rejection medication
after kidney transplant.
Participant Commitment: You are being asked to complete five short,
confidential surveys on the day of your annual clinic appointment.
There is no cost to you. All participants will be compensated $25.00 per
session.
PARTICIPATION IS LIMITED!

Please notify the clinic receptionist if you are interested in
participating in this study.
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